var title_f13_0_13312="ECG APB noncompensatory pause";
var content_f13_0_13312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) strips showing an atrial premature beat (APB) followed by a noncompensatory pause",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneous electrocardiographic recording from surface leads V1, II, and V5 shows an atrial premature beat (P') which is conducted with aberration. The P wave is different from that of the sinus beat and the PR interval is longer, due to delayed conduction in the atrioventricular node. A noncompensatory pause is present, ie, the interval measured from the sinus beat before and after the atrial premature beat is less than two sinus RR intervals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13312=[""].join("\n");
var outline_f13_0_13312=null;
var title_f13_0_13313="Fordyce spots - lip";
var content_f13_0_13313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fordyce spots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small yellow papules are present on the lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13313=[""].join("\n");
var outline_f13_0_13313=null;
var title_f13_0_13314="Morphea - hypopigmented";
var content_f13_0_13314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hypopigmented, firm, slightly shiny plaque is present on the forehead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13314=[""].join("\n");
var outline_f13_0_13314=null;
var title_f13_0_13315="Leiomyoma uterus B";
var content_f13_0_13315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bivalved hysterectomy specimen showing intramural and subserosal leiomyomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aron Schuftan, MD. Copyright &copy; Aron Schuftan, MD. Bivalved hysterectomy specimen showing intramural and subserosal leiomyomas Reproduced with permission from: Aron Schuftan, MD. Copyright &copy; Aron Schuftan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13315=[""].join("\n");
var outline_f13_0_13315=null;
var title_f13_0_13316="Mineral oil: Drug information";
var content_f13_0_13316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mineral oil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/46/33508?source=see_link\">",
"    see \"Mineral oil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/28/20931?source=see_link\">",
"    see \"Mineral oil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2605148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet&reg; Mineral Oil Enema [OTC];",
"     </li>",
"     <li>",
"      Kondremul&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2605152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative, Lubricant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2605174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Constipation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 15-45 mL/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Kondremul&reg;: 30-75 mL/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Liqui-Doss&reg;: 15-45 mL at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rectal (Fleet&reg; Mineral Oil): 118 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Fecal impaction or following barium studies:",
"     </b>",
"     Rectal (Fleet&reg; Mineral Oil): 118 mL as a single dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2605173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/28/20931?source=see_link\">",
"      see \"Mineral oil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Constipation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;1 year (practice guidelines):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Disimpaction: 15-30 mL per year of age; maximum 240 mL/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance: 1-3 mL/kg/day; adjust to induce daily bowel movement for 1-2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Kondremul&reg;: 10-25 mL/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Liqui-Doss&reg;: 5-15 mL at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rectal (Fleet&reg; Mineral Oil):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 2-12 years: 59 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Fecal impaction or following barium studies:",
"     </b>",
"     Rectal (Fleet&reg; Mineral Oil):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2-12 years: 59 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2605175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2605182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Microemulsion, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kondremul&reg;: 2.5 mL/5 mL (480 mL) [sugar free; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral: 100% (30 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral [heavy]: 100% (480 mL, 3840 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, rectal [enema]: 100% per 118 mL delivered dose (133 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Mineral Oil Enema: 100% per 118 mL delivered dose (133 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical: 100% (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical [light]: 100% (3840 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2605150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: oil",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2605177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Mineral oil may be more palatable if refrigerated. Administer on an empty stomach in an upright position.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Kondremul&reg;: Shake well before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Liqui-Doss&reg;: Shake well before use. Prior to use, mix with 120 mL of any beverage; administer only at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal (Fleet&reg; Mineral Oil): Gently insert enema rectally with patient lying on left side and left knee slightly bent, right knee drawn to chest.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2605155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of occasional constipation, relief of fecal impaction; removal of barium sulfate residues following barium administration",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9959247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2605162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Lipid pneumonitis with aspiration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Large doses may cause anal leakage causing anal itching, irritation, hemorrhoids, perianal discomfort, soiling of clothes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2605156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with colostomy or an ileostomy, appendicitis, ulcerative colitis, diverticulitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2605157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspiration: Lipid pneumonitis results from aspiration of mineral oil; risk is increased in patients in prolonged supine position or  conditions which interfere with swallowing or epiglottal function (eg, stroke, Parkinson's disease, Alzheimer's disease, esophageal dysmotility).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Due to potential for aspiration and other adverse effects, use in the elderly should be avoided (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC labeling: Healthcare provider should be contacted in case of sudden changes in bowel habits which last over 2 weeks or if abdominal pain, nausea, vomiting, or rectal bleeding occur following use; do not use for &gt;1 week, unless otherwise directed by healthcare provider. Do not use orally in children &lt;6 years of age or rectally in children &lt;2 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2605165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Mineral Oil may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, mineral oil may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant oral administration of mineral oil and multivitamins when possible; consider separating the administration of these agents by several hours to minimize the risk of interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phytonadione: Mineral Oil may decrease the serum concentration of Phytonadione. Specifically, mineral oil may decrease the absorption of phytonadione.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Mineral Oil may decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs.  Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcipotriene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The use of mineral oil for the treatment of constipation in pregnancy is not recommended (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The use of mineral oil for the treatment of constipation is not recommended for nursing women (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2605176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer with food or meals because of the risk of aspiration; prolonged administration of mineral oil may decrease absorption of lipid-soluble vitamins A, D, E, and K. Light sterile mineral oils are not for injection.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2605180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for response (stool frequency, consistency). Avoid use in patients who may aspirate.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5549703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet enema para Adulto (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2605166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eases passage of stool by decreasing water absorption and lubricating the intestine; retards colonic absorption of water",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2605168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Oral: 6-8 hours; Rectal: 2-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Site of action is the colon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/0/13316/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker SS, Liptak GS, Colletti RB, et al, &ldquo;Constipation in Infants and Children: Evaluation and Treatment. A Medical Position Statement of the North American Society for Pediatric Gastroenterology and Nutrition,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 1999, 29(5):612-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/0/13316/abstract-text/10554136/pubmed\" id=\"10554136\" target=\"_blank\">",
"        10554136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Constipation Guideline Committee, &ldquo;Clinical Practice Guideline. Evaluation and Treatment of Constipation of Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2006, 43(3):e1-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/0/13316/abstract-text/16954945/pubmed\" id=\"16954945\" target=\"_blank\">",
"        16954945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/0/13316/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10213 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13316=[""].join("\n");
var outline_f13_0_13316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605148\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605152\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605174\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605173\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605175\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605182\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605150\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605177\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605155\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9959247\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605162\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605156\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605157\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299716\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605165\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287015\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287016\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605176\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605180\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5549703\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605166\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2605168\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10213\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10213|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/46/33508?source=related_link\">",
"      Mineral oil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/28/20931?source=related_link\">",
"      Mineral oil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_0_13317="Quinine: Patient drug information";
var content_f13_0_13317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Quinine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     see \"Quinine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/12/19655?source=see_link\">",
"     see \"Quinine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3343866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Qualaquin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Quinine&reg;;",
"     </li>",
"     <li>",
"      Novo-Quinine;",
"     </li>",
"     <li>",
"      Quinine-Odan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705919",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to stop or treat leg cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691950",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat malaria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702842",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to quinine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Black water fever, G6PD deficiency, swelling of a nerve in the eye, long QT on ECG, low platelets, or myasthenia gravis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid foods or drinks that have quinine, such as tonic water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hearing loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pinpoint red spots on your skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight or in the way you see color.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11015 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13317=[""].join("\n");
var outline_f13_0_13317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343866\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216572\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030917\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030919\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030918\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030923\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030924\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030926\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030921\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030922\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030927\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030928\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=related_link\">",
"      Quinine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/12/19655?source=related_link\">",
"      Quinine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_0_13318="Hyphema";
var content_f13_0_13318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78964%7EEM%2F59855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78964%7EEM%2F59855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade I to II hyphema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A layered Grade I to II hyphema inferiorly is seen as well as an area of active bleeding from the superior iris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Kathryn A Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Boston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyphema, 100 percent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 17-year-old boy with Sturge-Weber syndrome has his entire pupil obscured by blood and massive subconjunctival hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trauma: Head and Neck. In: Atlas of Pediatric Emergency Medicine. Fleisher GR, Ludwig S, Baskin MN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13318=[""].join("\n");
var outline_f13_0_13318=null;
var title_f13_0_13319="Diseases potentially acquired by travel to East Asia";
var content_f13_0_13319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diseases potentially acquired by travel to East Asia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/0/13319/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13319/contributors\">",
"     David Murdoch, MD, MSc, DTM&amp;H, FRACP, FRCPA, FFSc(RCPA)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/0/13319/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13319/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/0/13319/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13319/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/0/13319/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The countries within the East Asia region include China, Japan, North Korea (Democratic People's Republic of Korea), South Korea (Republic of Korea), Mongolia, and Taiwan (",
"    <a class=\"graphic graphic_figure graphicRef78660 \" href=\"UTD.htm?11/19/11568\">",
"     figure 1",
"    </a>",
"    ). This is an area of diverse geography, from the high mountains, plateau, steppes, and desert of the West, to forested regions of the East, and tropical rain forests in the South. There are several areas within this region where the health risks do not differ appreciably from western Europe, North America and Australia, such as Japan, Hong Kong, South Korea, and Taiwan.",
"   </p>",
"   <p>",
"    Diseases potentially acquired by travel to East Asia are discussed here. Diseases associated with travel to Southeast Asia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12568?source=see_link\">",
"     \"Diseases potentially acquired by travel to Southeast Asia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ARTHROPOD-BORNE DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;China is the only country in the region with malaria endemic areas. However, Plasmodium vivax has reemerged along the demilitarized zone in Korea, thus far presenting minimal risk to tourists [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of malaria in China is restricted to certain rural areas. There is no risk in northern provinces bordering Mongolia, in the western provinces of Heilungkiang, Kirin, Ningsia Hui Tibet, and Tsinghai, or in Hong Kong and Macao. Among areas in which there is a malaria risk, the time of transmission is variable: north of latitude 33&ordm;N, transmission occurs from July to November; from latitude 33&ordm;N to 25&ordm;N, transmission occurs from May to December; south of latitude 25&ordm;N, transmission occurs year-round.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    resistance occurs in southern China, Hainan Island, and provinces bordering Myanmar, Laos, and Vietnam. In these regions",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    is the prophylactic agent of choice. In other malarious areas, chloroquine alone can be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12568?source=see_link\">",
"     \"Diseases potentially acquired by travel to Southeast Asia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Japanese encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Japanese encephalitis is an arboviral encephalitis that is endemic throughout much of tropical East Asia. Issues related to Japanese encephalitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5208?source=see_link\">",
"     \"Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dengue",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a resurgence of epidemic dengue fever in Taiwan and southern China since the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/2\">",
"     2",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=see_link\">",
"     \"Prevention and treatment of dengue virus infection\"",
"    </a>",
"    ). The main vector in this region is the daytime biting mosquito Aedes aegypti which typically breeds near human habitation. Most cases are reported from urban areas with high population densities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Typhus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrub typhus (caused by Orientia tsutsugamushi) may be found in scrub areas in China [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/3\">",
"     3",
"    </a>",
"    ], certain areas in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/4\">",
"     4",
"    </a>",
"    ], Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/5\">",
"     5",
"    </a>",
"    ], and South Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/6\">",
"     6",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26852?source=see_link\">",
"     \"Scrub typhus: Treatment and prevention\"",
"    </a>",
"    ). Murine typhus (caused by Rickettsia typhi) is also endemic in some regions of east Asia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27796?source=see_link\">",
"     \"The epidemiology and clinical manifestations of murine typhus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Yellow fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no risk for yellow fever in East Asia. However, due to the presence of the mosquito vector of yellow fever (Aedes aegypti), China and Taiwan require travelers to have a yellow fever vaccination certificate if they are coming from specified areas in South America or sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=see_link\">",
"     \"Yellow fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FOODBORNE AND WATERBORNE DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Travelers' diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most regions within East Asia are regarded as a intermediate to high risk for the development of travelers' diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/8\">",
"     8",
"    </a>",
"    ]. The most commonly isolated pathogens are similar to those in other intermediate to high risk areas of the world. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cholera",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of cholera are occasionally reported from this region. However, the risk for travelers is low and, under normal circumstances, cholera vaccination is not recommended for travelers to East Asia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29768?source=see_link\">",
"     \"Pathogenesis of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Typhoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoid is endemic throughout much of East Asia. The risk is low for travelers to Japan and Taiwan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hepatitis A and hepatitis E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A virus is endemic throughout East Asia, although there a very low risk for travelers to Japan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    .) Hepatitis E virus also appears to be widespread, but is uncommon in Japan. A seroprevalence of 10.7 percent was found in Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=see_link\">",
"     \"Hepatitis E virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Poliomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Western Pacific region (which includes all East Asian countries except North Korea) was declared free of poliomyelitis in 2001.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Schistosomiasis and other fluke infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis due to Schistosoma japonicum is endemic in parts of rural China. Fascioliasis (liver fluke), fasciolopsiasis (giant intestinal fluke), and paragonimiasis (lung fluke) can be acquired in most countries of the region. Clonorchiasis (oriental liver fluke) is common in China and Korea and is associated with ingestion of raw or inadequately cooked fish. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Severe acute respiratory syndrome (SARS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;SARS is a respiratory illness caused by a novel coronavirus, SARS-associated coronavirus (SARS-CoV) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/10\">",
"     10",
"    </a>",
"    ]. The disease is believed to have originated in southern China at the end of 2002. In February 2003 it crossed into Hong Kong and, a few days later, to Viet Nam, Singapore, Canada and Germany, and eventually spread to more than two dozen countries in North and South America, Europe, and Asia. In the East Asia region, Taiwan also experienced a large outbreak (",
"    <a class=\"external\" href=\"file://www.wpro.who.int/sars\">",
"     www.wpro.who.int/sars",
"    </a>",
"    ). In July 2003, new cases were no longer being reported, and SARS outbreaks worldwide were considered contained. Two isolated cases of SARS in laboratory workers occurred in Singapore in September 2003 and in Taiwan in December 2003. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=see_link\">",
"     \"Severe acute respiratory syndrome (SARS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalences of HIV infection are relatively low in the countries of East Asia. The mode of transmission is mainly heterosexual contact and intravenous drug use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hepatitis B and hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus is highly endemic throughout East Asia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .) Surveys among residents of the region have shown high prevalences of hepatitis C virus infection that range from 1.6 percent in South Korea to 10.7 percent in Mongolia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many, if not most, influenza epidemics have originated in China. The close association of birds and pigs in the region provide ideal conditions for genetic mixing and spread of influenza viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/12\">",
"     12",
"    </a>",
"    ]. This is almost certainly the case with the 1997 Hong Kong outbreak of a chicken H5N1 virus that caused 18 confirmed human cases with six deaths. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since 2003, a new strain of H5N1 influenza virus has spread among birds in Asia and elsewhere. There are an increasing number of human cases infected with this virus, including cases from China. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=see_link\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hantavirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hantavirus infections are zoonoses spread from small rodents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/13\">",
"     13",
"    </a>",
"    ]. The two main presentations in humans are hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). A severe form of HFRS caused by Hantaan virus occurs in Korea, China and Japan, and is associated with the striped field mouse (Apodemus agrarius). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4920?source=see_link\">",
"     \"Pathogenesis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Meningococcal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemics of meningococcal disease occurred in Mongolia in 1973 to 1974 and 1994 to 1995. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=see_link\">",
"     \"Diagnosis of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link\">",
"     \"Treatment and prevention of meningococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Plague",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of plague are still being reported from China and Mongolia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=see_link\">",
"     \"Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Rabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies is endemic throughout China, Korea and Mongolia, with dog bites the main source of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13319/abstract/15\">",
"     15",
"    </a>",
"    ]. Postexposure treatment is recommended following all potential exposures and prophylaxis should be considered by travelers spending significant periods of time in these countries. There is no rabies in Japan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tuberculosis is relatively common in some parts of East Asia, short-term travelers from countries of low endemicity are generally not considered at increased risk of infection. Thus, specific preventative measures are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Endemic fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major endemic fungal pathogen endemic to East Asia is Penicillium marneffei, which is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Penicillium marneffei infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER HAZARDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Motor vehicle accidents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury caused by motor vehicles is one of the greatest health hazards and a leading cause of death in travelers, although data specific to travelers to East Asia is lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Snake bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venomous snakes are present throughout east Asia. Naja spp. (Asian cobras), Bungarus multicinctus (Chinese krait), Trimeresurus flavoviridis (Japanese habu), Trimeresurus mucrosquamatus (Chinese habu), and Agkistrodon blomhoffii (mamushi) are responsible for most deaths and morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link\">",
"     \"Principles of snake bite management worldwide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Altitude illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are large high altitude areas within the East Asian region, especially in western China (including the Tibetan plateau) and Mongolia. Altitude illness is a high risk for travelers to these regions, especially those who ascend rapidly via motorized transport. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .) High altitude areas also exist in Japan and Taiwan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=see_link\">",
"       \"Patient information: Vaccines for travel (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       \"Patient information: General travel advice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4378510\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The countries within the East Asia region include China, Japan, North Korea (Democratic People's Republic of Korea), South Korea (Republic of Korea), Mongolia, and Taiwan (",
"      <a class=\"graphic graphic_figure graphicRef78660 \" href=\"UTD.htm?11/19/11568\">",
"       figure 1",
"      </a>",
"      ). There are several areas within this region where the health risks do not differ appreciably from western Europe, North America, and Australia, such as Japan, Hong Kong, South Korea, and Taiwan. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthropod-borne diseases that are endemic to certain parts of East Asia include malaria (especially in rural China), Japanese encephalitis, dengue, and typhus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Arthropod-borne diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Foodborne and waterborne infections in East Asia include travelers&rsquo; diarrhea, cholera, typhoid, hepatitis A, hepatitis E, schistosomiasis, and other fluke infections. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Foodborne and waterborne diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other infections that put travelers to East Asia at risk include HIV infection, hepatitis B, hepatitis C, influenza, hantavirus, meningococcus, plague, rabies, and Penicillium marneffei (especially among HIV-infected individuals). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Other infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noninfectious risks to travelers to East Asia include motor vehicle accidents, snake bites, and altitude sickness. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Other hazards'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/1\">",
"      Feighner BH, Pak SI, Novakoski WL, et al. Reemergence of Plasmodium vivax malaria in the republic of Korea. Emerg Infect Dis 1998; 4:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/2\">",
"      Qiu FX, Gubler DJ, Liu JC, Chen QQ. Dengue in China: a clinical review. Bull World Health Organ 1993; 71:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/3\">",
"      Fan MY, Walker DH, Yu SR, Liu QH. Epidemiology and ecology of rickettsial diseases in the People's Republic of China. Rev Infect Dis 1987; 9:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/4\">",
"      Horinouchi H, Murai K, Okayama A, et al. Prevalence of genotypes of Orientia tsutsugamushi in patients with scrub typhus in Miyazaki Prefecture. Microbiol Immunol 1997; 41:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/5\">",
"      Fang CT, Ferng WF, Hwang JJ, et al. Life-threatening scrub typhus with meningoencephalitis and acute respiratory distress syndrome. J Formos Med Assoc 1997; 96:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/6\">",
"      Yi KS, Chong Y, Covington SC, et al. Scrub typhus in Korea: importance of early clinical diagnosis in this newly recognized endemic area. Mil Med 1993; 158:269.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. International Travel and Health. Geneva: WHO, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/8\">",
"      Steffen R. Epidemiology of traveler's diarrhea. Clin Infect Dis 2005; 41 Suppl 8:S536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/9\">",
"      Lee SD, Wang YJ, Lu RH, et al. Seroprevalence of antibody to hepatitis E virus among Chinese subjects in Taiwan. Hepatology 1994; 19:866.",
"     </a>",
"    </li>",
"    <li>",
"     Emerg Infect Dis 2004; 10(2) [whole issue devoted to SARS].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/11\">",
"      Hepatitis C--global prevalence (update). Wkly Epidemiol Rec 1999; 74:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/12\">",
"      Webster RG. Influenza: an emerging disease. Emerg Infect Dis 1998; 4:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/13\">",
"      Butler JC, Peters CJ. Hantaviruses and hantavirus pulmonary syndrome. Clin Infect Dis 1994; 19:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/14\">",
"      Human plague in 1997. Wkly Epidemiol Rec 1999; 74:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13319/abstract/15\">",
"      Kureishi A, Xu LZ, Wu H, Stiver HG. Rabies in China: recommendations for control. Bull World Health Organ 1992; 70:443.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3885 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13319=[""].join("\n");
var outline_f13_0_13319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4378510\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ARTHROPOD-BORNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Japanese encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dengue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Typhus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Yellow fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FOODBORNE AND WATERBORNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cholera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Typhoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hepatitis A and hepatitis E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Poliomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Schistosomiasis and other fluke infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hepatitis B and hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hantavirus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Meningococcal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Plague",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Rabies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Endemic fungi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER HAZARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Motor vehicle accidents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Snake bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Altitude illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4378510\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3885|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/19/11568\" title=\"figure 1\">",
"      Map of East Asia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27285?source=related_link\">",
"      Diagnosis of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=related_link\">",
"      Diagnosis of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12568?source=related_link\">",
"      Diseases potentially acquired by travel to Southeast Asia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=related_link\">",
"      Epidemiology and clinical manifestations of Penicillium marneffei infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=related_link\">",
"      Epidemiology and diagnosis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=related_link\">",
"      Epidemiology of Neisseria meningitidis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=related_link\">",
"      Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=related_link\">",
"      Hepatitis E virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5208?source=related_link\">",
"      Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29768?source=related_link\">",
"      Pathogenesis of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4920?source=related_link\">",
"      Pathogenesis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=related_link\">",
"      Prevention and treatment of dengue virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=related_link\">",
"      Principles of snake bite management worldwide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26852?source=related_link\">",
"      Scrub typhus: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=related_link\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27796?source=related_link\">",
"      The epidemiology and clinical manifestations of murine typhus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=related_link\">",
"      Yellow fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_0_13320="Etravirine: Drug information";
var content_f13_0_13320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etravirine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/56/10117?source=see_link\">",
"    see \"Etravirine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/8/9352?source=see_link\">",
"    see \"Etravirine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5606106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Intelence&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5994283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Intelence&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5605506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Non-nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5605725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of HIV-1 infection:",
"     </b>",
"     Oral: 200 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F14290658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/8/9352?source=see_link\">",
"      see \"Etravirine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of HIV-1 infection:",
"     </b>",
"     Oral: Children 6 to &lt;18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;16 kg to &lt;20 kg: 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;20 kg to &lt;25 kg: 125 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;25 kg to &lt;30 kg: 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;30 kg: 200 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5605726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Due to extensive protein binding, significant removal by hemodialysis or peritoneal dialysis is unlikely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5605727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh class C): No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5605757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intelence&reg;: 25 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intelence&reg;: 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5605504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5605728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after meals. If unable to swallow tablets, may disperse tablets in water (&ge;1 teaspoonful [enough to cover tablets]); stir well (until milky), add additional water (or may add milk or orange juice), and drink immediately.  Rinse glass several times (with water, milk or orange juice) and swallow entire contents to ensure administration of dose.  Do not use grapefruit juice, carbonated beverages or warm (&gt;40&deg;C) water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5605507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with at least two additional antiretroviral agents in treatment-experienced patients exhibiting viral replication with documented non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13811173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Etravirine [U.S. and multiple international markets] may be confused with ethaverine [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5605592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (&ge;grade 2: 10% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Cholesterol (total) increased (&le;300 mg/dL: 20%; &gt;300 mg/dL: 8%), hyperglycemia (&le;250 mg/dL: 15%; 251-500 mg/dL: 4%), LDL increased (&le;190 mg/dL: 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (&le;750 mg/dL: 9%; &gt;750 mg/dL: 4% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (children and adolescents &ge;2%), amylase increased (&gt;5 x ULN: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (&le;5 x ULN: 6%; &gt;5 x ULN: 3%), AST increased (&le;5 x ULN: 6%; &gt;5 x ULN: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy (&ge; grade 2: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (&le;1.8 x ULN: 6%; &gt;1.8 x ULN: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Amnesia, anemia (including hemolytic), angina, angioedema, anorexia, atrial fibrillation, diabetes mellitus, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, GERD, gynecomastia, hemorrhagic stroke, hematemesis, hepatic failure, hepatic steatosis, hepatitis, hepatomegaly, hypersensitivity reaction, hypersomnia, hypoesthesia, immune reconstitution syndrome, insomnia, lipohypertrophy/dystrophy, MI, pancreatitis, renal failure, rhabdomyolysis, seizure, Stevens-Johnson syndrome, syncope, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5605587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5605588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions/hypersensitivity: Severe and possibly life-threatening skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme) and hypersensitivity reactions ranging from rash (including drug rash with eosinophilia and systemic symptoms [DRESS]) and/or constitutional symptoms to occasional organ dysfunction (including hepatic failure) have been reported; discontinue immediately with signs or symptoms of severe skin reaction or hypersensitivity. Self-limiting (with continued therapy) mild-to-moderate rashes (higher incidence in females) were also observed in clinical trials (pediatric and adult), usually during second week of therapy initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of etravirine with some drugs may require cautious use, may not be recommended, or may require dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not for use in treatment-naive patients, or experienced patients without evidence of viral mutations conferring resistance to NNRTIs and PIs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5605666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate), CYP2C9 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5605665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Etravirine may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Etravirine may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine.  Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: Etravirine may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine. Etravirine may increase the serum concentration of Artemether.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: Etravirine may decrease the serum concentration of Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Etravirine may decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Etravirine may decrease the serum concentration of Diazepam. Etravirine may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Etravirine may increase the serum concentration of Digoxin.  Management: Monitor serum digoxin concentrations and adjust dose as needed. In patients initiating a regimen of digoxin with etravirine, digoxin should be initiated at the lowest dose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Etravirine may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Etravirine may decrease the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Etravirine may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may increase.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Etravirine may decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased.  Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Etravirine may decrease the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: Etravirine may decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased.  Management: For the treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex, consider changing to alternative agent, such as azithromycin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Etravirine may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Etravirine may decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Etravirine. Management: The manufacturer of etravirine states these drugs should not be used in combination",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: Etravirine may decrease the serum concentration of Phosphodiesterase 5 Inhibitors.  Management: No empiric dosage adjustments are recommended with concomitant therapy; however, dose of the phosphodiesterase inhibitor may need to be altered based on clinical response.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Etravirine may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Etravirine may increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir).  Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atazanavir; Fosamprenavir; Ritonavir; Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Etravirine may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): May decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: May decrease the serum concentration of Etravirine. Management: Avoid concomitant use with rifabutin if a protease inhibitor/ritonavir combination is also used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Etravirine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, St. Johns Wort may increase the metabolism of Reverse Transcriptase Inhibitors (Non-Nucleoside).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Etravirine may decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5605669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food increases absorption of etravirine by ~50%. Management: Take after meals and maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effects of etravirine. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5605508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5605509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been noted in animal reproduction studies. Etravirine crosses the placenta. Based on limited data, dose adjustments are not needed in pregnant women. However, because available data in pregnant women are insufficient, the DHHS Perinatal HIV Guidelines do not recommend use in antiretroviral-naive women unless other alternatives are not available. Hypersensitivity reactions (including hepatic toxicity and rash) are more common in women on NNRTI therapy; it is not known if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5605511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5606112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5605672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6133123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Intelence Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (120): $260.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (120): $1041.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $1041.26",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5605730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol, triglycerides, serum glucose, hepatic transaminases (if signs or symptoms of hypersensitivity develop); signs of skin rash, signs and symptoms of infection",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F11434564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitoring of etravirine levels is not routinely recommended.  Insufficient data are available to recommend a target trough concentration (DHHS, 2013)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Intelence (AR, AT, AU, BE, BR, CH, CL, CN, CO, CZ, DE, DK, EE, FR, GB, GR, HK, HN, IE, IL, IT, KP, NL, NO, NZ, PE, PL, PT, RU, SE, SG, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5605755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a non-nucleoside reverse transcriptase inhibitor, etravirine has activity against HIV-1 by binding to reverse transcriptase. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities, including HIV-1 replication. It does not require intracellular phosphorylation for antiviral activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5605679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Increased 50% with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99.9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily by CYP3A4, 2C9, and 2C19; major metabolites exhibit ~10% of parent drug activity against wild-type HIV",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 41 hours (&plusmn; 20 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (94%, up to 86% as unchanged drug); urine (1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katlama C, Haubrich R, Lalezari J, et al, \"Efficacy and Safety of Etravirine in Treatment-Experienced, HIV-1 Patients: Pooled 48 Week Analysis of Two Randomized, Controlled Trials,\"",
"      <i>",
"       AIDS",
"      </i>",
"      , 2009, 23(17):2289-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/0/13320/abstract-text/19710593/pubmed\" id=\"19710593\" target=\"_blank\">",
"        19710593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lazzarin A, Campbell T, Clotet B, et al, &ldquo;Efficacy and Safety of TMC125 (Etravirine) in Treatment-Experienced HIV-1-Infected Patients in DUET-1: 24-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet,",
"      </i>",
"      2007, 370(9581):39-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/0/13320/abstract-text/17617271/pubmed\" id=\"17617271\" target=\"_blank\">",
"        17617271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Madruga JV, Cahn P, Grinsztejn B, et al, &ldquo;Efficacy and Safety of TMC125 (Etravirine) in Treatment-Experienced HIV-1-Infected Patients in DUET-1: 24-Week Results From a Randomised, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9581):29-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/0/13320/abstract-text/17617270/pubmed\" id=\"17617270\" target=\"_blank\">",
"        17617270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8902 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13320=[""].join("\n");
var outline_f13_0_13320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5606106\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994283\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605506\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605725\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14290658\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605726\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605727\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605757\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605504\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605728\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605507\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13811173\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605592\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605587\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605588\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605666\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605665\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605669\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605508\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605509\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605511\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5606112\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605672\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6133123\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605730\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11434564\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961935\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605755\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605679\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8902\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8902|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/56/10117?source=related_link\">",
"      Etravirine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/8/9352?source=related_link\">",
"      Etravirine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_0_13321="Pasteurella infections";
var content_f13_0_13321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pasteurella infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/0/13321/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13321/contributors\">",
"     David J Weber, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13321/contributors\">",
"     William A Rutala, PhD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13321/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/0/13321/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13321/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13321/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/0/13321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13321/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/0/13321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pasteurella are small Gram-negative coccobacilli that are primarily commensals or pathogens of animals. However, these organisms can cause a variety of infections in humans, usually as a result of cat scratches, or cat or dog bites or licks.",
"   </p>",
"   <p>",
"    Pasteurella infections will be reviewed here. Other infections related to dog and cat bites or scratches are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=see_link\">",
"     \"Zoonoses from dogs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=see_link\">",
"     \"Zoonoses from cats\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The members of the genus Pasteurella are small, nonmotile, nonspore-forming organisms. In Gram stained specimens, they generally appear as a single bacillus, often with bipolar staining, but may also be seen in pairs or short chains (",
"    <a class=\"graphic graphic_picture graphicRef70953 \" href=\"UTD.htm?36/1/36880\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pasteurella spp are aerobic, facultatively anaerobic, and grow well at 37&ordm;C on 5 percent sheep blood (the preferred culture medium), chocolate, or Mueller-Hinton agar; growth is uncommon on MacConkey's agar. Most strains recovered from clinical specimens are catalase, oxidase, indole, sucrose, and decarboxylate ornithine positive. The indole-positive species exhibit a mouse-like odor. Media containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    have been used to select for pasteurellae [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/1\">",
"     1",
"    </a>",
"    ]. Potential bacterial virulence factors include capsule lipopolysaccharide, a cytotoxin, iron acquisition proteins, and other surface structures including homologues of the Bordetella pertussis filamentous hemagglutinin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human infections have been reported from P. multocida (the most common pathogen and type species for the genus), including P. multocida subsp multocida, P. multocida subsp septica, and P. multocida subsp gallicida; P. canis; P. dagmatis; and P. stomatis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. All except P. canis (associated only with dogs) are associated with dogs and cats. The subspecies of P. multocida can be differentiated by PCR fingerprinting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/6\">",
"     6",
"    </a>",
"    ]. Related species include [P.] aerogenes, [P.] bettyae, [P.] caballi, [P.] pneumotropica, [P.] trehalosi, and [P.] haemolytica [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complete genome sequence of one strain of Pasteurella multocida has been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typing of P. multocida has traditionally been done by serology. There are five capsular serogroups and 16 somatic serotypes; most human infections are due to serotypes A, D, and F [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. New typing methods rely on molecular methods [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pasteurella spp are found worldwide. P. multocida is a component of the normal upper respiratory tract flora of fowl and mammals, especially felines. Other Pasteurella spp can be found in the oral cavity of a variety of animals including dogs (P. canis); cats and dogs (P. dagmatis, P. stomatis); pigs and hamsters ([P.] aerogenes); and horses ([P.] caballi).",
"   </p>",
"   <p>",
"    Pasteurella can cause a variety of diseases in animals, such as fowl cholera in domestic fowl, shipping fever in cattle (P. multocida is a cause of secondary infection following parainfluenza infection), hemorrhagic septicemia in cattle and lambs, fibrinous pneumonia in cattle, snuffles in rabbits, and other focal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular analysis by pulsed-field gel electrophoresis (PFGE) has documented transmission from dogs and cats to humans both by direct and indirect contact [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/10\">",
"     10",
"    </a>",
"    ]. Wild and domestic animals are the main reservoirs for human infection, including healthy cats and dogs and diseased rabbits [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Most human infections are caused by dog or cat bites, although licks from these animals have also been associated with infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Licking of distal areas of non-intact skin by cats and dogs have led to seeding of proximal prosthetic joints such as a total knee arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/14\">",
"     14",
"    </a>",
"    ]. Kissing animals has also been reported as the source in Pasteurella in several cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human-to-human horizontal transmission has also been documented, including transmission via close contact with colonized individuals and transmission via contaminated blood products [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. Vertical transmission can occur via transplacental infection, endometritis, or genital tract colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pasteurella spp are the most frequent isolates from both dog and cat bites (50 and 75 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Human infection with Pasteurella also may result from bites of other felines (eg, tigers, lions, panthers, cougars), horses, pigs, rats, rabbits, and wolves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pasteurella can cause serious soft tissue infections and, less commonly, septic arthritis, osteomyelitis, sepsis, and meningitis, particularly in infants and other immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/25\">",
"     25",
"    </a>",
"    ]. Infections with P. multocida can be divided into three categories (",
"    <a class=\"graphic graphic_table graphicRef64084 \" href=\"UTD.htm?17/30/17901\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellulitis following animal bites or scratches; bites and scratches can also result in abscesses, necrotizing soft tissue infections, septic arthritis, and osteomyelitis",
"     </li>",
"     <li>",
"      Oral and respiratory infections, usually in the setting of chronic pulmonary disease",
"     </li>",
"     <li>",
"      Serious invasive infection often unrelated to animal bites, such as meningitis, intraabdominal infection, endocarditis, or ocular infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Soft tissue infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical soft tissue infections with P. multocida usually occur after cat bites, cat scratches, or dog bites [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/12,24,26-28\">",
"     12,24,26-28",
"    </a>",
"    ], but may also occur following cat or dog licks of nonintact skin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. P. multocida wound infections characteristically have a very rapid development of an intense inflammatory response. Most patients develop symptoms within 24 hours of the initial injury, and as early as three hours after a cat bite [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain and swelling are prominent. Purulent drainage is noted in about 40 percent of patients, lymphangitis in about 20 percent, and regional adenopathy in 10 percent. Cellulitis often occurs within 24 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/26,29,30\">",
"     26,29,30",
"    </a>",
"    ]. Necrotizing fasciitis may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/12,28\">",
"     12,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone and joint infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. multocida can cause septic arthritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteomyelitis. Septic arthritis without osteomyelitis most commonly involves a single joint, usually the knee. There is a predilection for involvement of prosthetic joints or joints damaged by rheumatoid arthritis or degenerative joint disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/14,31-33\">",
"     14,31-33",
"    </a>",
"    ]. More than 50 percent of patients who have septic arthritis also have altered host defenses from corticosteroids or alcoholism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of septic arthritis involve a cat or dog bite distal to the involved joint, without direct penetrating injury to the joint; approximately one-third of cases are not preceded by an animal bite or scratch.",
"   </p>",
"   <p>",
"    Osteomyelitis results from either local extension of soft tissue infection or direct inoculation into the periosteum by the cat or dog bite. Osteomyelitis usually is preceded by significant wound infection and cellulitis.",
"   </p>",
"   <p>",
"    Cat bites are more likely to lead to bone infection than are dog bites, presumably because the small, sharp teeth of the cat more easily penetrate the periosteum. The combination of septic arthritis and osteomyelitis almost always occurs after cat bites of the hand, resulting in osteomyelitis of the phalanx and interphalangeal arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Respiratory infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. multocida can cause a variety of upper and lower respiratory tract infections including glossitis, pharyngitis, sinusitis, otitis media, mastoiditis, epiglottitis, tracheobronchitis, pneumonia, empyema, and lung abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/26,34-37\">",
"     26,34-37",
"    </a>",
"    ]. The majority of patients with P. multocida respiratory tract infections have underlying lung disease such as chronic obstructive lung disease (COPD) or chronic bronchitis.",
"   </p>",
"   <p>",
"    Pneumonia is the most common pleuropulmonary infection caused by P. multocida, with most cases occurring in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/26\">",
"     26",
"    </a>",
"    ]. In one series of 108 patients with Pasteurella pleuropulmonary infection, 49 had pneumonia, 37 tracheobronchitis, 25 empyema, and 3 lung abscess. Bacteremia was found in 55 percent of the patients in whom blood cultures were obtained. The overall mortality in this series was 29 percent. An underlying disease was found in 93 percent of patients.",
"   </p>",
"   <p>",
"    The clinical course of Pasteurella respiratory tract infections is nonspecific. Common symptoms include fever, malaise, dyspnea, and pleuritic chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/26,34\">",
"     26,34",
"    </a>",
"    ]. Approximately two-thirds of patients have fever. The onset of the illness may be gradual or abrupt. In patients with pneumonia, chest examination often reveals localized findings such as dullness, rhonchi, or wheezes. The chest radiograph most commonly demonstrates lobar consolidation, but multilobar and diffuse infiltrates have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pasteurella spp can cause a variety of other serious invasive infections such as meningitis, bacteremia, endocarditis, and peritonitis. Serious invasive infection has been reported after exposure to animals in the absence of a bite or a scratch [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/11,17,38-43\">",
"     11,17,38-43",
"    </a>",
"    ]. In addition, P. multocida can rarely be associated with in utero infection leading to fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/44\">",
"     44",
"    </a>",
"    ], acute suppurative thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/45\">",
"     45",
"    </a>",
"    ], and urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the uncommon manifestations of P. multocida infection have been noted in case reports (",
"    <a class=\"graphic graphic_table graphicRef64084 \" href=\"UTD.htm?17/30/17901\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pasteurella multocida meningitis is a disease of the extremes of life [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/19,21,26,39,40,47\">",
"     19,21,26,39,40,47",
"    </a>",
"    ]. Fifty percent of cases have involved infants younger than one year of age, and 30 percent have involved adults older than 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/26,39,47\">",
"     26,39,47",
"    </a>",
"    ]. Meningitis or brain abscess can occur after a perforating animal bite to an infant's skull [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cerebrospinal fluid (CSF) generally contains polymorphonuclear leukocytes with a low glucose and elevated protein, similar to other pyogenic infections. Gram stain of the CSF is positive in 80 percent of patients, but the organisms are frequently misidentified as Haemophilus influenzae or Neisseria meningitidis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/13/16600?source=see_link\">",
"     \"Epidemiology and clinical features of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia with P. multocida most commonly accompanies a localized infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/26,49\">",
"     26,49",
"    </a>",
"    ]. Bacteremia occurs in 25 to 50 percent of patients with pneumonia, meningitis, and septic arthritis due to P. multocida. Many patients with bacteremia have evidence of significant liver dysfunction or other predisposing diseases including diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/26,49-53\">",
"     26,49-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocarditis is a rare complication of P. multocida sepsis, with about 15 cases of P. multocida endocarditis reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Infection may involve native or prosthetic valves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Abdominal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraabdominal infections caused by P. multocida include peritonitis and appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/50,56-61\">",
"     50,56-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritonitis due to P. multocida, especially in the setting of continuous ambulatory peritoneal dialysis, has been reported in more than 15 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/56-59,62\">",
"     56-59,62",
"    </a>",
"    ]. P. multocida was isolated along with more traditional intraabdominal pathogens. Gram stain of the peritoneal fluid was negative in approximately one-half of the cases.",
"   </p>",
"   <p>",
"    Cats were the source of almost all peritoneal infections. In most of the cases associated with peritoneal dialysis (approximately two-thirds), the dialysis tubing had been punctured by the cat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of P. multocida infection is made by isolation of the organism in culture. Specimens should be cultured on appropriate medium to facilitate the isolation of P. multocida. The organism grows readily on sheep blood agar. Because P. multocida infection is uncommon, the organism may be misidentified initially, especially on Gram stains of sputum or CSF. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pasteurella spp are the first organisms to consider in any patient who presents with a soft tissue infection following cat scratches, or cat or dog bites or licks. Such infections are characterized by rapid onset and an intense inflammatory response, similar to group A streptococcal (Streptococcus pyogenes) soft tissue infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Septic arthritis in abnormal or prosthetic joints may follow distal animal bites or scratches. Patients with impaired host defenses (eg, liver insufficiency, diabetes mellitus, malignancy) and animal contact may develop serious infections with Pasteurella spp, such as spontaneous bacterial peritonitis.",
"   </p>",
"   <p>",
"    P. multocida may be isolated from respiratory tract samples of patients with pleuropulmonary disease. Because P. multocida respiratory tract infections are rare and have no distinctive characteristics, P. multocida may not be suspected as the infecting pathogen. In addition, Pasteurella may be mistaken for H. influenzae, Moraxella catarrhalis, Neisseria spp, or Acinetobacter spp on sputum Gram stain. However, when recovered in culture, Pasteurella should be recognized as a serious pathogen and the patient treated accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pasteurella spp, including P. multocida, are susceptible to a number of antibiotics (",
"    <a class=\"graphic graphic_table graphicRef70131 \" href=\"UTD.htm?4/52/4941\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. Treatment for suspected P. multocida should, in general, use one of the antibiotics recommended by the Clinical and Laboratory Standards Institute (CLSI) for susceptibility testing, as described below [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For isolates from bite wounds, routine susceptibility testing is usually not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/68\">",
"     68",
"    </a>",
"    ]. Multiple organisms are often present in these specimens and empiric therapy directed towards these organisms is generally effective for P. multocida as well. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Empiric therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Testing of isolates from normally sterile sources (blood cultures, deep tissue, implanted prosthetic devices) and also respiratory specimens may be warranted, particularly in immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/68\">",
"     68",
"    </a>",
"    ]. Additional considerations for testing include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent infection",
"     </li>",
"     <li>",
"      Clinical failure of initial antibiotic therapy",
"     </li>",
"     <li>",
"      Allergy to or intolerance of the drugs of choice",
"     </li>",
"     <li>",
"      Possible resistance to a drug that is being considered for therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antibiotic susceptibility testing should follow the guidelines of the CLSI [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/68\">",
"     68",
"    </a>",
"    ] and be performed only by laboratories experienced with the recommended broth microdilution MIC procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, treatment for suspected P. multocida should use one of antibiotics recommended by CLSI for susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/68\">",
"     68",
"    </a>",
"    ]. CLSI has provided susceptibility break points for P. multocida against the following agents:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Penicillins (penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cephalosporins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Quinolones (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tetracyclines (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Macrolides (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Others (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      [TMP-SMX])",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Soft tissue infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     General management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of a P. multocida soft tissue infection associated with an animal bite should begin with appropriate management of the bite wound [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such management includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation for the presence of life-threatening complications (eg, pneumothorax).",
"     </li>",
"     <li>",
"      Evaluation of nerve function, tendon integrity, and vascular supply.",
"     </li>",
"     <li>",
"      Copious irrigation of large wounds.",
"     </li>",
"     <li>",
"      Determination of the need for tetanus or rabies postexposure prophylaxis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link\">",
"       \"Rabies immune globulin and vaccine\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local health regulations may require the reporting of animal bites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antimicrobial therapy, whether administered by mouth or intravenously, should be directed at the polymicrobial infection that frequently occurs after animal bites (eg, Pasteurella spp, oral anaerobes, and Staphylococcus aureus). The combination of a penicillin with a beta-lactamase inhibitor is widely recommended for patients with no history of penicillin allergy. Examples include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    for oral therapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    for intravenous therapy. Alternative regimens for patients allergic to penicillin are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Definitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive therapy should be based upon the results of wound cultures. Therapy is usually continued for 7 to 10 days.",
"   </p>",
"   <p>",
"    Pasteurella spp, including P. multocida, are usually susceptible to a number of antibiotics including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ), advanced cephalosporins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ), and carbapenems (eg, imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef70131 \" href=\"UTD.htm?4/52/4941\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Susceptibility testing is warranted in special circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Susceptibility testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most cases of Pasteurella soft-tissue infection resolve with appropriate oral antibiotics and wound drainage, when indicated. We suggest penicillin VK as first-line therapy because of its narrow spectrum, low cost, safety, and proven efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, penicillin resistant isolates from human infections with P. multocida have occasionally been described. In one in vitro study of 122 isolates of P. multocida, the MIC90 for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    was at the break point for defining susceptible strains (0.5",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Penicillin VK is dosed follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Penicillin VK (25 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO divided in three or four doses for children beyond the newborn period; maximum adult dose 500",
"      <span class=\"nowrap\">",
"       mg/dose",
"      </span>",
"      three or four times per day [total dose 2",
"      <span class=\"nowrap\">",
"       g/day])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative regimens for patients allergic to penicillin or those infected with beta-lactamase-producing strains include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (750 mg PO once per day); levofloxacin is not approved for children &lt;18 years of age.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      (2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO divided in one or two doses for children &ge;8 years of age, maximum daily dose 100 to 200 mg; 100 mg PO twice per day in adults) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Extended spectrum cephalosporins, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"       cefixime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"       cefpodoxime",
"      </a>",
"      may be used in patients with non-immediate hypersensitivity reactions to penicillin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"       Cefixime",
"      </a>",
"      (8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO divided in one or two doses for children; 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO divided in one or two doses for adults)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"       Cefpodoxime",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO divided in two doses for children, maximum daily dose 800 mg; 400 mg PO twice per day for adults)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical failures have been noted in patients treated with oral macrolides (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ), semi-synthetic penicillins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    ), first-generation cephalosporins (eg, cephalothin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"     cefadroxil",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. These agents have poor in vitro activity against P. multocida and should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Intravenous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for intravenous antibiotics in patients with Pasteurella soft tissue infection include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to resolve or worsening infection with oral therapy",
"     </li>",
"     <li>",
"      Inability to tolerate oral antibiotics (eg, vomiting)",
"     </li>",
"     <li>",
"      Underlying host defense defects (eg, cirrhosis)",
"     </li>",
"     <li>",
"      Evidence of sepsis or metastatic spread (eg, endocarditis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two potential intravenous regimens include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (240",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      day intravenously [IV] divided in three doses, maximum daily dose 12 to 18 g for children; 3.37 g IV every six to eight hours for adults, maximum daily dose 12 to 18 g)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      (100 to 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day [of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      component] IV divided in four doses for children, maximum daily dose 6 to 12 g; 3 g IV every six hours for adults)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     Amoxicillin-clavulanate",
"    </a>",
"    generally is recommended to complete 10 to 14 days of therapy for serious soft tissue infections following an animal bite.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    -clavulanate is dosed as described above. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Empiric therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Broad spectrum cephalosporins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    ) are an alternative for patients with non-immediate hypersensitivity reactions to penicillin. These drugs are active against Pasteurella species in vitro, but there is limited experience using them for the treatment of Pasteurella [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     Aztreonam",
"    </a>",
"    may be an acceptable alternative for patients with immediate hypersensitivity to penicillins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/70\">",
"     70",
"    </a>",
"    ]. TMP-SMX and quinolones (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) are other options [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Septic arthritis and osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic arthritis can be treated with high doses of parenteral antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    , 2 million units every 4 hours for adults or 200,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day in 4 to 6 divided doses for children, with a maximum daily dose of 24 million units) and multiple aspirations of the joint. Alternatives in the penicillin-allergic patient include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (non-life threatening allergy),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    , or a quinolone (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Antimicrobial therapy is generally continued for four to six weeks. Removal of the prosthesis is usually required for the resolution of a prosthetic joint infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link&amp;anchor=H17#H17\">",
"     \"Septic arthritis in adults\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least four weeks of total intravenous plus oral antibiotics are required to treat osteomyelitis. Intravenous penicillin may be administered initially as described above; therapy can be completed orally if clinically appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Duration and efficacy of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Serious invasive infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious invasive infections, including respiratory infections, should be treated with high-dose intravenous antibiotics as described for septic arthritis and osteomyelitis. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Septic arthritis and osteomyelitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Data on management of Pasteurella are limited to case report literature [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Choice of antibiotics is as outlined above for other deep infections. The optimal duration is uncertain; success has been reported with six weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for Pasteurella infections depends upon the site of infection and underlying medical conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most soft tissues infections resolve with appropriate oral antibiotics and wound drainage, when indicated.",
"     </li>",
"     <li>",
"      Approximately 50 percent of patients with osteomyelitis experience slow healing, nonunion, joint fusion, limitations of motion, or residual deformity.",
"     </li>",
"     <li>",
"      Functional outcome of P. multocida infections of the hand is poor [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mortality in Pasteurella meningitis, bacteremia and endocarditis are approximately 25 percent, 30 percent, and 30 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13321/abstract/39,49,54\">",
"       39,49,54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=see_link\">",
"       \"Patient information: Animal bites (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most Pasteurella infections in humans are caused by cat scratches, or dog or cat bites or licks. Pasteurella infection should be considered in any patient who presents with a soft tissue infection following such exposure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      P. multocida wound infections are characterized by the rapid development of an intense inflammatory response within 24 hours of the initial injury. Pain and swelling are prominent. Purulent drainage, lymphangitis, and regional lymphadenopathy also may be present. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Soft tissue infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of P. multocida infection is made by isolation of the organism in culture; the organism grows readily on sheep blood agar. Susceptibility testing should be performed in selected cases. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Susceptibility testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of P. multocida soft tissue infection associated with an animal bite should begin with management of the bite wound. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'General management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"       \"Soft tissue infections due to dog and cat bites\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"       \"Initial management of animal and human bites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Empiric therapy for infected animal wounds should include an agent active against P. multocida and other potential co-pathogens. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Empiric therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"       \"Soft tissue infections due to dog and cat bites\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"       \"Initial management of animal and human bites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Definitive therapy for Pasteurella infection should be based upon the results of wound cultures and susceptibility testing (if indicated) (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Definitive therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Susceptibility testing'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Most Pasteurella soft tissue infections can be treated orally. We suggest penicillin as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (in patients &ge;18 years),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (in patients &ge;8 years), and extended spectrum cephalosporins (in patients with non-life threatening allergies) are acceptable alternatives for patients who are allergic to penicillin. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Definitive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for intravenous therapy include failure to improve with oral therapy, inability to tolerate oral therapy, underlying host defense defects, septic arthritis, osteomyelitis, or serious invasive infection. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Intravenous therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Septic arthritis and osteomyelitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Serious invasive infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     von Graevenitz A, Zbinden R, Mutters R. Actinobacillus, Capnocytophaga, Eikenella, Kingella, Pasteurella, and other fastidious or rarely encountered Gram-negative rods. In: Manual of Clinical Microbiology, 9th Ed, Murray PR (Ed), American Society for Microbiology, Washington, DC 2007. p.621.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/2\">",
"      Boyce JD, Adler B. How does Pasteurella multocida respond to the host environment? Curr Opin Microbiol 2006; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/3\">",
"      Harper M, Boyce JD, Adler B. Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS Microbiol Lett 2006; 265:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/4\">",
"      Holst E, Rollof J, Larsson L, Nielsen JP. Characterization and distribution of Pasteurella species recovered from infected humans. J Clin Microbiol 1992; 30:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/5\">",
"      Donnio PY, Lerestif-Gautier AL, Avril JL. Characterization of Pasteurella spp. strains isolated from human infections. J Comp Pathol 2004; 130:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/6\">",
"      Hunt Gerardo S, Citron DM, Claros MC, et al. Pasteurella multocida subsp. multocida and P. multocida subsp. septica differentiation by PCR fingerprinting and alpha-glucosidase activity. J Clin Microbiol 2001; 39:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/7\">",
"      May BJ, Zhang Q, Li LL, et al. Complete genomic sequence of Pasteurella multocida, Pm70. Proc Natl Acad Sci U S A 2001; 98:3460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/8\">",
"      Townsend KM, Boyce JD, Chung JY, et al. Genetic organization of Pasteurella multocida cap Loci and development of a multiplex capsular PCR typing system. J Clin Microbiol 2001; 39:924.",
"     </a>",
"    </li>",
"    <li>",
"     Acha PN, Szyfres B. Zoonoses and Communicable Diseases Common To Man and Animals, 3rd Ed, Pan American Health Organization, Washington, DC 2001. Vol 1, p.199.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/10\">",
"      Miyoshi S, Hamada H, Miyoshi A, et al. Pasteurella multocida pneumonia: zoonotic transmission confirmed by molecular epidemiological analysis. Geriatr Gerontol Int 2012; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/11\">",
"      Perrin I, Blanc P, Karam T, Carbajal R. [Meningitis and osteitis caused by Pasteurella multocida in a three-month-old infant]. Arch Pediatr 2003; 10:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/12\">",
"      Chang K, Siu LK, Chen YH, et al. Fatal Pasteurella multocida septicemia and necrotizing fasciitis related with wound licked by a domestic dog. Scand J Infect Dis 2007; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/13\">",
"      Chun ML, Buekers TE, Sood AK, Sorosky JI. Postoperative wound infection with Pasteurella multocida from a pet cat. Am J Obstet Gynecol 2003; 188:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/14\">",
"      Heym B, Jouve F, Lemoal M, et al. Pasteurella multocida infection of a total knee arthroplasty after a \"dog lick\". Knee Surg Sports Traumatol Arthrosc 2006; 14:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/15\">",
"      Kawashima S, Matsukawa N, Ueki Y, et al. Pasteurella multocida meningitis caused by kissing animals: a case report and review of the literature. J Neurol 2010; 257:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/16\">",
"      Siahanidou T, Gika G, Skiathitou AV, et al. Pasteurella multocida Infection in a neonate: evidence for a human-to-human horizontal transmission. Pediatr Infect Dis J 2012; 31:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/17\">",
"      Wade T, Booy R, Teare EL, Kroll S. Pasteurella multocida meningitis in infancy - (a lick may be as bad as a bite). Eur J Pediatr 1999; 158:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/18\">",
"      Bryant BJ, Conry-Cantilena C, Ahlgren A, et al. Pasteurella multocida bacteremia in asymptomatic plateletpheresis donors: a tale of two cats. Transfusion 2007; 47:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/19\">",
"      Zaramella P, Zamorani E, Freato F, et al. Neonatal meningitis due to a vertical transmission of Pasteurella multocida. Pediatr Int 1999; 41:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/20\">",
"      Guillet C, Join-Lambert O, Carbonnelle E, et al. Pasteurella multocida sepsis and meningitis in 2-month-old twin infants after household exposure to a slaughtered sheep. Clin Infect Dis 2007; 45:e80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/21\">",
"      Nakwan N, Nakwan N, Atta T, Chokephaibulkit K. Neonatal pasteurellosis: a review of reported cases. Arch Dis Child Fetal Neonatal Ed 2009; 94:F373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/22\">",
"      Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med 1999; 340:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/23\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/24\">",
"      Westling K, Farra A, Cars B, et al. Cat bite wound infections: a prospective clinical and microbiological study at three emergency wards in Stockholm, Sweden. J Infect 2006; 53:403.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pasturella infections. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th Ed, Pickering, LK (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.493.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/26\">",
"      Weber DJ, Wolfson JS, Swartz MN, Hooper DC. Pasteurella multocida infections. Report of 34 cases and review of the literature. Medicine (Baltimore) 1984; 63:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/27\">",
"      Weber DJ, Hansen AR. Infections resulting from animal bites. Infect Dis Clin North Am 1991; 5:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/28\">",
"      Hamamoto Y, Soejima Y, Ogasawara M, et al. Necrotizing fasciitis due to Pasteurella multocida infection. Dermatology 1995; 190:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/29\">",
"      Westling K, Bygdeman S, Engkvist O, Jorup-R&ouml;nstr&ouml;m C. Pasteurella multocida infection following cat bites in humans. J Infect 2000; 40:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/30\">",
"      Nseir W, Giladi M, Moroz I, et al. A retrospective six-year national survey of P. multocida infections in Israel. Scand J Infect Dis 2009; 41:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/31\">",
"      Spagnuolo PJ. Pasteurella multocida infectious arthritis. Am J Med Sci 1978; 275:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/32\">",
"      Mehta H, Mackie I. Prosthetic joint infection with Pasturella multocida following cat scratch: a report of 2 cases. J Arthroplasty 2004; 19:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/33\">",
"      Heydemann J, Heydemann JS, Antony S. Acute infection of a total knee arthroplasty caused by Pasteurella multocida: a case report and a comprehensive review of the literature in the last 10 years. Int J Infect Dis 2010; 14 Suppl 3:e242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/34\">",
"      Klein NC, Cunha BA. Pasteurella multocida pneumonia. Semin Respir Infect 1997; 12:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/35\">",
"      Byrd RP Jr, Roy TM. Pasteurella multocida respiratory infection: an important cat-associated zoonosis. Arch Intern Med 2003; 163:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/36\">",
"      Marinella MA. Community-acquired pneumonia due to Pasteurella multocida. Respir Care 2004; 49:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/37\">",
"      Harris PJ, Osswald MB. Pasteurella multocida epiglottitis: A review and report of a new case with associated chronic lymphocytic leukemia. Ear Nose Throat J 2010; 89:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/38\">",
"      Hirsh D, Farrell K, Reilly C, Dobson S. Pasteurella multocida meningitis and cervical spine osteomyelitis in a neonate. Pediatr Infect Dis J 2004; 23:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/39\">",
"      Green BT, Ramsey KM, Nolan PE. Pasteurella multocida meningitis: case report and review of the last 11 y. Scand J Infect Dis 2002; 34:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/40\">",
"      Thompson CM Jr, Pappu L, Levkoff AH, Herbert KH. Neonatal septicemia and meningitis due to Pasteurella multocida. Pediatr Infect Dis 1984; 3:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/41\">",
"      Boerlin P, Siegrist HH, Burnens AP, et al. Molecular identification and epidemiological tracing of Pasteurella multocida meningitis in a baby. J Clin Microbiol 2000; 38:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/42\">",
"      Octavio J, Rosenberg W, Conte JE Jr. Surgical-wound infection with Pasteurella multocida from pet dogs. N Engl J Med 2001; 345:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/43\">",
"      Cohen-Adam D, Marcus N, Scheuerman O, et al. Pasteurella multocida septicemia in a newborn without scratches, licks or bites. Isr Med Assoc J 2006; 8:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/44\">",
"      Waldor M, Roberts D, Kazanjian P. In utero infection due to Pasteurella multocida in the first trimester of pregnancy: case report and review. Clin Infect Dis 1992; 14:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/45\">",
"      McLaughlin SA, Smith SL, Meek SE. Acute suppurative thyroiditis caused by Pasteurella multocida and associated with thyrotoxicosis. Thyroid 2006; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/46\">",
"      Cortez JM, Imam AA, Ang JY. Pasteurella multocida urinary tract infection in a pediatric patient with end-stage renal disease. Pediatr Infect Dis J 2007; 26:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/47\">",
"      O'Neill E, Moloney A, Hickey M. Pasteurella multocida meningitis: case report and review of the literature. J Infect 2005; 50:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/48\">",
"      Klein DM, Cohen ME. Pasteurella multocida brain abscess following perforating cranial dog bite. J Pediatr 1978; 92:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/49\">",
"      Kimura R, Hayashi Y, Takeuchi T, et al. Pasteurella multocida septicemia caused by close contact with a domestic cat: case report and literature review. J Infect Chemother 2004; 10:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/50\">",
"      Ashley BD, Noone M, Dwarakanath AD, Malnick H. Fatal Pasteurella dagmatis peritonitis and septicaemia in a patient with cirrhosis: a case report and review of the literature. J Clin Pathol 2004; 57:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/51\">",
"      Migliore E, Serraino C, Brignone C, et al. Pasteurella multocida infection in a cirrhotic patient: case report, microbiological aspects and a review of literature. Adv Med Sci 2009; 54:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/52\">",
"      Tattevin P, Souala F, Gautier AL, et al. Diabetes in patients with pasteurellosis. Scand J Infect Dis 2005; 37:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/53\">",
"      Olshtain-Pops K, Yinnon AM. Pasteurella multocida sepsis--should immunocompromised patients give up their pets? Isr Med Assoc J 2008; 10:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/54\">",
"      Nettles RE, Sexton DJ. Pasteurella multocida prosthetic valve endocarditis: case report and review. Clin Infect Dis 1997; 25:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/55\">",
"      Fayad G, Modine T, Mokhtari S, et al. Pasteurella multocida aortic valve endocarditis: case report and literature review. J Heart Valve Dis 2003; 12:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/56\">",
"      Cooke FJ, Kodjo A, Clutterbuck EJ, Bamford KB. A case of Pasteurella multocida peritoneal dialysis-associated peritonitis and review of the literature. Int J Infect Dis 2004; 8:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/57\">",
"      Malik A, Al Aly Z, Mailey KS, Bastani B. Pasteurella multocida peritoneal dialysis-associated peritonitis: a report of two cases and review of the literature. J Nephrol 2005; 18:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/58\">",
"      Loghman-Adham M. Pasteurella multocida peritonitis in patients undergoing peritoneal dialysis. Pediatr Nephrol 1997; 11:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/59\">",
"      Mat O, Moenens F, Beauwens R, et al. Indolent Pasteurella multocida peritonitis in a CCPD patient. 25 years of \"cat-bite peritonitis\": a review. Perit Dial Int 2005; 25:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/60\">",
"      Tamaskar I, Ravakhah K. Spontaneous bacterial peritonitis with Pasteurella multocida in cirrhosis: case report and review of literature. South Med J 2004; 97:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/61\">",
"      Raffi F, David A, Mouzard A, et al. Pasteurella multocida appendiceal peritonitis: report of three cases and review of the literature. Pediatr Infect Dis 1986; 5:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/62\">",
"      Rondon-Berrios H, Trevejo-Nunez GJ. Pets or pest: peritoneal dialysis-related peritonitis due to Pasteurella multocida. J Microbiol Immunol Infect 2010; 43:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/63\">",
"      Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. J Antimicrob Chemother 2001; 48:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/64\">",
"      Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species. Antimicrob Agents Chemother 2002; 46:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/65\">",
"      Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. J Antimicrob Chemother 2002; 50:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/66\">",
"      Citron DM, Warren YA, Fernandez HT, et al. Broth microdilution and disk diffusion tests for susceptibility testing of Pasteurella species isolated from human clinical specimens. J Clin Microbiol 2005; 43:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/67\">",
"      Lion C, Conroy MC, Carpentier AM, Lozniewski A. Antimicrobial susceptibilities of Pasteurella strains isolated from humans. Int J Antimicrob Agents 2006; 27:290.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Methods for antimicrobial dilutin and disk susceptibility testing of infrequently isolated or fastidious bacteria. Approved standard M45-A. Clinical and Laboratory Standards Institute; Wayne, PA 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/69\">",
"      Jorgensen JH, Hindler JF. New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis 2007; 44:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/70\">",
"      Jordan EF, Nye MB, Luque AE. Successful treatment of Pasteurella multocida meningitis with aztreonam. Scand J Infect Dis 2006; 38:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13321/abstract/71\">",
"      Lucas GL, Bartlett DH. Pasteurella multocida infection in the hand. Plast Reconstr Surg 1981; 67:49.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3129 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13321=[""].join("\n");
var outline_f13_0_13321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone and joint infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Respiratory infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Abdominal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Soft tissue infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - General management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Definitive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Intravenous therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Septic arthritis and osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Serious invasive infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3129\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3129|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/1/36880\" title=\"picture 1\">",
"      Pasteurella multocida microscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3129|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/30/17901\" title=\"table 1\">",
"      Sites of Pasteurella infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/52/4941\" title=\"table 2\">",
"      Rx of Pasteurella multocida",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/13/16600?source=related_link\">",
"      Epidemiology and clinical features of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=related_link\">",
"      Zoonoses from cats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=related_link\">",
"      Zoonoses from dogs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_0_13322="Immunizations for healthcare providers";
var content_f13_0_13322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunizations for healthcare providers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/0/13322/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13322/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/0/13322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13322/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/0/13322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/0/13322/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/0/13322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare providers are at risk for exposure to and acquisition of vaccine preventable diseases. This risk can be minimized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Strict adherence to handwashing [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rapid institution of appropriate isolation for patients with known or suspected communicable diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maintaining up to date immunizations in healthcare providers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional precautions should be taken by personnel working in the microbiology or pathology laboratory, such as no eating or drinking in areas where specimens are processed and use of protective equipment when culturing pathogens such as Mycobacterium tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthcare providers are also susceptible to nosocomial exposure to tuberculosis from hospitalized patients. This risk is even greater in certain regions of the world where admission rates for TB are extremely high, such as Zimbabwe [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/6\">",
"     6",
"    </a>",
"    ]. Indications for TB skin testing, test interpretation, and treatment are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of immunizations to prevent infection in healthcare providers will be reviewed here. The value of handwashing and isolation guidelines is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHICH HEALTHCARE PROVIDERS SHOULD BE IMMUNIZED AGAINST VACCINE-PREVENTABLE DISEASES?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4539738\">",
"    <span class=\"h2\">",
"     Immunization policies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention (CDC) recommends that immunization programs be provided for all healthcare providers in hospitals, health departments, private physician offices, nursing homes, schools and laboratories and emergency medical personnel (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"UTD.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/7\">",
"     7",
"    </a>",
"    ]. All medical facilities or health departments that provide direct patient care are encouraged to formulate and implement a comprehensive immunization policy for all healthcare providers. This policy should describe exactly what the risk of exposure to vaccine preventable diseases is, according to job description.",
"   </p>",
"   <p>",
"    Recommendations for immunization should be based upon the risk of exposure. All new employees should receive a prompt review of their immunization status prior to starting to care for patients; in addition, all employees should have an annual review to ensure that immunizations remain up to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4539745\">",
"    <span class=\"h2\">",
"     Medical documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization is recommended when prior vaccine administration cannot be documented, unless the healthcare provider has a contraindication to vaccine administration. Serologic screening for immunity is generally",
"    <strong>",
"     not",
"    </strong>",
"    considered cost-effective. All vaccine-related information should be documented in the healthcare provider's medical record [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4539752\">",
"    <span class=\"h2\">",
"     Failure to immunize",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite these recommendations, large numbers of healthcare providers lack immunity to hepatitis B, influenza, measles, mumps, and rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/9-15\">",
"     9-15",
"    </a>",
"    ]. There are two major reasons for failure of the recommendations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some healthcare providers refuse to be immunized. In one study of medical school clinical employees, for example, only 77 percent completed the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      series [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/9\">",
"       9",
"      </a>",
"      ]. Reasons why healthcare providers refuse vaccines for these diseases include: desire to avoid medications, concern about side effects, belief that the vaccine is ineffective (influenza), and belief that the risk of acquiring disease is low (hepatitis B) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/14,16\">",
"       14,16",
"      </a>",
"      ]. Factors that predict acceptance of the influenza vaccine included older age, higher economic status, and prior work absenteeism [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second reason for failure to immunize healthcare providers is inadequate policies and inconsistent enforcement of policies. In a community-wide outbreak of measles that occurred in 1996, only 47 percent of medical facilities had an immunization policy and only 21 percent of facilities met Advisory Committee on Immunization Practices (ACIP) recommendations and enforced their policy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/15\">",
"       15",
"      </a>",
"      ]. There has also been wide variability in immunization policies for healthcare providers. In a national survey of children's hospitals, more than 90 percent of the institutions surveyed reported cases of each of the following diseases in their institution in the last five years: measles, tuberculosis, hepatitis B, varicella, and influenza [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/18\">",
"       18",
"      </a>",
"      ]. Education and interventions such as the use of mobile carts that facilitate access to immunization increases immunization rates, but levels remain sub-optimal [",
"      <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WHICH VACCINES SHOULD BE PROVIDED TO HEALTHCARE PROVIDERS?",
"    </span>",
"    &nbsp;&mdash;&nbsp;General recommendations regarding immunization of immunocompetent healthcare providers have been published by the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/7,20\">",
"     7,20",
"    </a>",
"    ], the Association for Professionals in Infection and Epidemiology, Inc (APIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/21\">",
"     21",
"    </a>",
"    ], the ACP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/22\">",
"     22",
"    </a>",
"    ], and infectious diseases experts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. The general approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All healthcare providers should be immune to measles, mumps, rubella, and varicella.",
"     </li>",
"     <li>",
"      All healthcare providers with potential exposure to blood or body fluids should be immune to hepatitis B.",
"     </li>",
"     <li>",
"      All healthcare providers should be offered annual immunization with influenza vaccine.",
"     </li>",
"     <li>",
"      All health care workers should receive a one-time dose of Tdap as soon as possible, unless they are certain that they have received Tdap.",
"     </li>",
"     <li>",
"      All healthcare providers should either be offered immunizations that are routinely recommended for adults, such as tetanus, diphtheria, and pneumococcal vaccine, or be referred to their primary care provider.",
"     </li>",
"     <li>",
"      At risk healthcare providers and laboratory personnel should be offered the following vaccines: polio, meningococcal, BCG, rabies, plague, typhoid, and hepatitis A.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunocompromised healthcare providers require special considerations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hepatitis B vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2004, there were an estimated 304 hepatitis B virus infections that occurred among healthcare providers in the United States, a substantial decrease from the estimated 10,000 annual infections that occurred in the early 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of acquiring hepatitis B infection depends on the frequency of percutaneous and permucosal exposures to blood or body fluids containing blood [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/10,28-31\">",
"     10,28-31",
"    </a>",
"    ]. Such exposures are common in healthcare providers who are routinely exposed to blood and blood-contaminated fluids. A survey of New York surgeons in 1988 revealed that 86 percent had at least one puncture injury in the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/32\">",
"     32",
"    </a>",
"    ]. Similar findings were noted in a 1991 survey of orthopedic surgeons; 39 percent of responders reported a percutaneous blood exposure in the last month [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HBV is more transmissible than hepatitis C virus (HCV) or the human immunodeficiency virus (HIV). Between six and 30 percent of individuals who have a percutaneous injury with a sharp contaminated with HBV will become infected with the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/34\">",
"     34",
"    </a>",
"    ]. Disease transmission rates are lower after mucosal contact or contact through nonintact skin, but transmission has even been reported after ocular exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/35\">",
"     35",
"    </a>",
"    ] and in a respiratory therapist with severe exudative dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/36\">",
"     36",
"    </a>",
"    ]. Infection with HBV has also occurred in healthcare providers who cannot recall any percutaneous exposure; in this setting infection has been attributed to small breaks in the skin or inapparent inoculation through mucous membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A predisposing factor to transmission is that healthcare providers may not know that patients are infected with HBV. This was illustrated in a review of specimens submitted to the chemistry laboratory in an urban teaching hospital; only 28 percent of the HBsAg-positive specimens were labeled as hazardous as required by the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a variety of sources of HBV other than blood-containing specimens in the healthcare environment. These include: contaminated medical instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/39-44\">",
"     39-44",
"    </a>",
"    ], environmental surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/45\">",
"     45",
"    </a>",
"    ], and contaminated file cards among laboratory technicians [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/46\">",
"     46",
"    </a>",
"    ]. In dialysis units, transmission of HBV continues to be associated with the use of common-dose medications and shared equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to acquisition of HBV, infected healthcare providers (including surgeons) have been responsible for numerous outbreaks in patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. In the United States and United Kingdom, healthcare providers who are HBeAg-positive are restricted from performing invasive procedures. However, transmission of HBV has also been described from HBeAg-negative surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/52\">",
"     52",
"    </a>",
"    ]. These surgeons had detectable HBV DNA in serum and were infected with precore stop codon mutants that prevent the secretion of HBeAg [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link&amp;anchor=H6#H6\">",
"     \"Serologic diagnosis of hepatitis B virus infection\", section on 'Hepatitis B e antigen and antibody'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Occupational Safety and Health Act of 1991 mandates that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    be made available at the employer's expense to all healthcare providers who are occupationally exposed to blood or other infectious materials or sharps [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preimmunization serologic screening with anti-HBs is indicated for healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/7\">",
"     7",
"    </a>",
"    ]. Additionally, for healthcare providers at high risk for HBV (eg, born in regions with at least two percent HBsAg prevalence, HIV-infected, history of intravenous drug use, high-risk sexual behavior, on hemodialysis), screening for past infection with HBsAg and",
"    <span class=\"nowrap\">",
"     anti-HBc/anti-HBs",
"    </span>",
"    is indicated prior to vaccination. &nbsp;",
"   </p>",
"   <p>",
"    Previously unvaccinated or incompletely vaccinated healthcare providers who may be exposed to blood or other infectious body fluids and who do not have serologic evidence of immunity to or infection with HBV should undergo vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/7\">",
"     7",
"    </a>",
"    ]. Protective titers (anti-HBs &gt;10",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    develop in 95 to 99 percent of healthy adults who receive three intramuscular doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/55\">",
"     55",
"    </a>",
"    ]. The rate decreases with increasing age to 86 percent in the fourth decade and 47 percent in the sixth decade [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/56\">",
"     56",
"    </a>",
"    ]. Doses are usually administered on a 0, 1 and 6-month schedule in the deltoid, although accelerated schedules of 0,1 and 4 months or 0,1 and 2 months may be considered for healthcare providers at highest risk (eg, surgeons and those working in hemodialysis units). Accelerated schedules result in more rapid antibody rise but may result in lower peak titers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. A fourth dose of the vaccine at 12 months is recommended for healthcare providers who are immunized using the accelerated schedule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two available vaccines, Recombivax HB and Energix-B are equally immunogenic and can be used interchangeably to complete the immunization series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/55\">",
"     55",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    may be administered with other vaccines and can safely be used during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, 5 to 21 percent of healthcare providers do not develop a protective level of anti-HBs after three doses of vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. In addition to increasing age as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/56\">",
"     56",
"    </a>",
"    ], greater immunocompromise, current smoking, and higher body mass index are associated with lower rates of seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/55,59-61\">",
"     55,59-61",
"    </a>",
"    ]. Thus, all healthcare providers should have their anti-HBs level checked one to two months after the third dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link&amp;anchor=H18#H18\">",
"     \"Hepatitis B virus vaccination\", section on 'Management of nonresponders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately one-half of those who do not respond to the first three doses of the vaccine will respond to additional doses; thus, healthcare providers who have not developed a protective response may receive up to three additional doses of the vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/62\">",
"     62",
"    </a>",
"    ]. An adequate antibody response is seen in 15 to 25 percent after one additional dose and in 50 percent after three additional doses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/63\">",
"     63",
"    </a>",
"    ]. Titers can be checked after the administration of each dose, or at the end of the second three-dose series. Healthcare providers who do not respond to a total of six doses of the vaccine are considered nonresponders and should receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) for post-exposure prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fall in antibody titers over time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine-induced antibodies to hepatitis B decline over time, and approximately 60 percent of initial responders will have undetectable levels twelve or more years after immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/64\">",
"     64",
"    </a>",
"    ]. Despite declining antibody levels, healthcare providers who initially responded to the vaccine remain protected against clinical disease and viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/65\">",
"     65",
"    </a>",
"    ]. Thus, checking antibody levels more than once and providing booster doses are",
"    <strong>",
"     not",
"    </strong>",
"    recommended. Asymptomatic hepatitis B infections have occurred in vaccinated patients (detected by the presence of antibody to hepatitis B core antigen), but these infections result in long lasting immunity and are not associated with hepatitis B-associated liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influenza virus is spread from person to person by small particle aerosol transmission. Transmission by fomites or contaminated hands is another potential way the virus can be nosocomially-acquired. Patients with influenza have led to nosocomial transmission of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], and infected staff have transmitted the virus to patients and other staff [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquisition of influenza in medical staff results in absenteeism and disruption of healthcare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In addition, nosocomial outbreaks have been responsible for significant morbidity and mortality in nursing homes and other long-term facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/71-77\">",
"     71-77",
"    </a>",
"    ]. These problems can be reduced by vaccination. This was illustrated in a study in which patients in facilities where influenza immunization rates of staff were greater than 60 percent had less influenza-related morbidity and mortality than patients in facilities where less than 60 percent of the staff were vaccinated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since influenza infection in staff and patients is common, ranging between 25 and 80 percent, the CDC has published extensive guidelines for the prevention and control of nosocomial influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/19,79,80\">",
"     19,79,80",
"    </a>",
"    ]. The American Academy of Pediatrics, American College of Physicians, American Public Health Association, Infectious Diseases Society of America, and Society of Healthcare Epidemiology of America have all endorsed mandatory influenza vaccination for all health care workers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A central part of the prevention strategy is annual immunization (between mid-October and mid-November) of healthcare providers, particularly physicians, nurses, employees of nursing homes or other long-term health facilities who have contact with patients or residents, and providers of home care to high risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/64,81\">",
"     64,81",
"    </a>",
"    ]. The vaccine is also recommended for anyone who wishes to reduce his or her chance of becoming ill with influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/81\">",
"     81",
"    </a>",
"    ]. In both adults and pediatric healthcare providers, influenza vaccine is cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/82\">",
"     82",
"    </a>",
"    ] and, in one study, reduced absenteeism by 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the intranasal influenza vaccine was first introduced, healthcare providers under the age of 50 years were excluded from receiving it if they worked with immunosuppressed patients. This recommendation from the ACIP was modified in 2004 to exclude healthcare providers caring for severely immunosuppressed individuals especially during the time of greatest immunosuppression (eg, during hospitalization) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/81\">",
"     81",
"    </a>",
"    ]. If a healthcare provider receives intranasal vaccine, he or she should not have contact with severely immunosuppressed patients for seven days. The intranasal vaccine is only approved for healthy individuals aged 2 to 49 years and is considered an acceptable alternative to the inactivated vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Measles, mumps, and rubella vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there were only 86, 352, and 234 cases of measles, mumps, and rubella, respectively, that were reported to the CDC in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], these diseases are a major health hazard for hospital personnel. The risk of acquiring measles in hospital personnel is estimated to be thirteen times greater than for the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All three diseases are transmissible by the air-droplet route (and measles can also be transmitted by the airborne route) before the infected person has clinically recognizable illness. Nosocomial outbreaks of all three diseases have been reported in the last 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/15,88-90\">",
"     15,88-90",
"    </a>",
"    ]. Transmission of measles has occurred after visits to the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/91\">",
"     91",
"    </a>",
"    ] and in outpatient areas, even if the patient with measles had left the area more than one hour earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]; in addition rubella has been transmitted from children with congenital rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, healthcare providers are considered at high risk of exposure to measles, mumps, and rubella and need full immunity to these diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link\">",
"     \"Measles-mumps-rubella vaccination in high risk adults\"",
"    </a>",
"    .) Although people born before 1957 have been considered immune to measles, 4 to 9 percent of healthcare providers born before 1957 were found to be susceptible to measles in outbreak investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/90,95-97\">",
"     90,95-97",
"    </a>",
"    ]. Similarly, approximately 6 percent of healthcare providers born before 1957 are susceptible to rubella [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All healthcare providers (medical with and without patient care responsibilities, non-medical, paid, volunteer, full-time, part-time, student) should have a formal assessment of immunity to measles and mumps regardless of year of birth and those who are susceptible should be immunized [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. The same recommendation is made for all female healthcare providers with respect to rubella immunity and immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/20\">",
"     20",
"    </a>",
"    ]. Strict definitions of evidence of measles, mumps, and rubella immunity should be used. Serologic screening before immunization is generally not considered necessary for people who have documentation of appropriate vaccination or other acceptable evidence of immunity to measles, mumps, and rubella, such as laboratory confirmation of disease. Most individuals born prior to 1957 were likely infected naturally and can generally be presumed immune. However, for unvaccinated healthcare providers born before 1957 who lack laboratory evidence of measles or mumps immunity or laboratory confirmation of disease, vaccination with two doses of MMR given at least 28 days apart should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/7\">",
"     7",
"    </a>",
"    ]. During outbreaks of measles or mumps, such individuals should receive two doses of MMR vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link&amp;anchor=H4#H4\">",
"     \"Measles-mumps-rubella vaccination in high risk adults\", section on 'Which adults should receive the MMR vaccine and how should it be administered?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two doses of the trivalent MMR vaccine are needed for full immunity. However, bivalent or monovalent vaccines can be used in healthcare providers who have acceptable evidence of immunity to one or two of the viruses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link\">",
"     \"Measles-mumps-rubella vaccination in high risk adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19145659\">",
"    <span class=\"h2\">",
"     Pertussis vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pertussis is highly contagious with secondary attack rates among susceptible household contacts of more than 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/98\">",
"     98",
"    </a>",
"    ]. Despite widespread use of diphtheria, pertussis, and tetanus immunization of children, the incidence of pertussis has been increasing. There were 25,827 cases reported in 2004 (the largest number since 1959) and 16,858 cases in 2009, with localized outbreaks in California, Michigan and Ohio [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/99\">",
"     99",
"    </a>",
"    ]. In addition, it is likely that the cases reported to the CDC are an underestimate, because many cases of pertussis are not diagnosed.",
"   </p>",
"   <p>",
"    Although the highest attack rate of pertussis occurs in children under one year of age, approximately 60 percent of cases now occur in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/100\">",
"     100",
"    </a>",
"    ]. Survey data from the CDC found that Tdap coverage was less than 6 percent in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. In June 2012, the ACIP recommended that all adults, including those aged 65 and older, receive a dose of Tdap, regardless of the time since their last Td dose [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/103\">",
"     103",
"    </a>",
"    ]. This recommendation is applicable to healthcare personnel, but healthcare personnel should receive Tdap as soon as feasible, if they have not previously received this vaccine. Two Tdap vaccines are approved in the United States for adults under age 65: Boostrix&trade; and ADACEL&trade;. Because data are not available to evaluate the effectiveness of a single dose of Tdap for the prevention of secondary cases of pertussis, it is still recommended that exposed adults receive prophylaxis, as discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Varicella vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of varicella in the healthcare environment is important for two reasons: varicella is highly contagious, with secondary attack rates in susceptible household members varying from 61 to 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/104\">",
"     104",
"    </a>",
"    ]; and adults are at high risk of developing complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32200?source=see_link\">",
"     \"Prevention and control of varicella in hospitals\"",
"    </a>",
"    .) Immunocompromised adults and pregnant women are at particular risk of morbidity and mortality caused by varicella. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Person-to-person, droplet, and airborne transmission from either primary varicella or herpes zoster may be the way in which healthcare providers are exposed to the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/105\">",
"     105",
"    </a>",
"    ]. Nosocomial outbreaks continue to be reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/106-109\">",
"     106-109",
"    </a>",
"    ], with source patients including those who did not have evidence of clinical disease at the time of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/110\">",
"     110",
"    </a>",
"    ]. Even if patients with varicella can be promptly placed in negative pressure rooms, as recommended by the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/2\">",
"     2",
"    </a>",
"    ], susceptible healthcare providers remain at risk of acquiring disease that is transmitted before clinical disease is apparent.",
"   </p>",
"   <p>",
"    An estimated 14 to 40 percent of healthcare providers are susceptible to varicella. While 97 to 99 percent of those who have a positive history of varicella are seropositive, variable percentages of those with an unclear or no history of varicella are seropositive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC and many infectious diseases experts recommend the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    for healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/64\">",
"     64",
"    </a>",
"    ], because of the risk of serious complications of natural disease in adults, the risk of further transmission in healthcare facilities, and immunization is cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/111\">",
"     111",
"    </a>",
"    ]. The CDC and the American Academy of Pediatrics recommend that susceptible employees be removed from work beginning 8 to 10 days after exposure through day 21 after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/23,64\">",
"     23,64",
"    </a>",
"    ]. Varicella control strategies other than immunization are reviewed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/2,64\">",
"     2,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32200?source=see_link\">",
"     \"Prevention and control of varicella in hospitals\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Healthcare providers should be screened for varicella immunity at the time of employment. Current employees can be screened at the time of their annual tuberculosis and immunization evaluation. Those with a laboratory or healthcare provider confirmation of prior disease or written documentation of two",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    doses can be considered immune, but all others should have serologic testing, ideally with the latex agglutination test. Those who are seronegative who do not have a contraindication to immunization should be immunized with two doses of the varicella vaccine administered at least four weeks apart. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32200?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention and control of varicella in hospitals\", section on 'Prevention of varicella among health care workers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postimmunization serology is",
"    <strong>",
"     not",
"    </strong>",
"    cost-effective because commercial tests lack the sensitivity to detect lower antibody levels associated with immunization and because more sensitive assays (such as the gpELISA test that is not commercially available) show that 99 percent of adults seroconvert after immunization. Secondary transmission of varicella after immunization has not yet occurred in the absence of a vesicular postimmunization rash [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/112\">",
"     112",
"    </a>",
"    ]. Healthcare providers who develop an injection site rash may continue to work only if the lesions are covered. Employees who develop a generalized rash must be furloughed, since the rash may be caused by natural varicella, coincidentally associated with immunization.",
"   </p>",
"   <p>",
"    Unfortunately, seroconversion does not always result in full protection against varicella. The management of healthcare providers following varicella exposure is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32200?source=see_link&amp;anchor=H18#H18\">",
"     \"Prevention and control of varicella in hospitals\", section on 'Management of exposed previously vaccinated health care workers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32200?source=see_link&amp;anchor=H19#H19\">",
"     \"Prevention and control of varicella in hospitals\", section on 'Management of exposed susceptible health care workers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vaccines that may be indicated in specified settings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     BCG vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the risk of infection with M. tuberculosis is low and the efficacy of the Bacille Calmette-Guerin (BCG) vaccine is uncertain, routine immunization of healthcare providers is",
"    <strong>",
"     not",
"    </strong>",
"    recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/113\">",
"     113",
"    </a>",
"    ]. Another problem is that BCG vaccination interferes with the use of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    that is used to detect infection with M. tuberculosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=see_link\">",
"     \"BCG vaccination\"",
"    </a>",
"    .) Tuberculosis control strategies other than immunization are beyond the scope of this discussion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/2,113\">",
"     2,113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BCG vaccination may be considered in the following situations and only as a secondary prevention strategy after instituting comprehensive infection control practices [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high percentage of patients are infected with M. tuberculosis strains that are resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Transmission of drug-resistant strains of M. tuberculosis to healthcare providers is considered likely.",
"     </li>",
"     <li>",
"      Comprehensive infection control precautions have been unsuccessfully implemented.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    BCG vaccination is not recommended for healthcare providers in low-risk settings and is contraindicated in immunocompromised persons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hepatitis A vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A is highly endemic in the United States. The incidence appears to have been decreasing in recent years with 10,777 cases reported to the CDC in 2001 (provisional data) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/114\">",
"     114",
"    </a>",
"    ] compared with 31,582 cases in 1995. However, both reports underestimate the true burden of disease because of underreporting of symptomatic infection and lack of recognition of asymptomatic disease.",
"   </p>",
"   <p>",
"    Even though hepatitis A is common, with 11 to 22 percent of symptomatic patients requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/115\">",
"     115",
"    </a>",
"    ], nosocomial outbreaks are rare when proper infection control practices are followed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/113,116\">",
"     113,116",
"    </a>",
"    ]. Nosocomial outbreaks have been associated with contaminated blood transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/117,118\">",
"     117,118",
"    </a>",
"    ], contaminated food [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/119,120\">",
"     119,120",
"    </a>",
"    ] and poor infection control practices, particularly when caring for patients with fecal incontinence or unrecognized hepatitis A infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/121-124\">",
"     121-124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary strategy for preventing hepatitis A infection in healthcare providers is strict infection control practices. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    routinely recommended for any group of healthcare providers. It may be provided on an individual basis for healthcare providers who have other risk factors for acquiring hepatitis A. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Meningococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nosocomial transmission of Neisseria meningitidis is rare, although direct contact with respiratory secretions of infected persons has resulted in transmission to healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/113\">",
"     113",
"    </a>",
"    ]. The primary approach to prevention of acquisition of meningococcal disease is to adhere to precautions that prevent exposure to respiratory droplets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/2,113\">",
"     2,113",
"    </a>",
"    ]. Routine immunization of healthcare providers is not recommended. However, healthcare providers for whom meningococcal vaccination would otherwise be",
"    <a class=\"external\" href=\"file://www.cdc.gov/vaccines/schedules/downloads/adult/adult-schedule.pdf\">",
"     recommended",
"    </a>",
"    , such as those with functional asplenia or complement component deficiencies or with travel planned to epidemic or hyperendemic areas, should be vaccinated (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"UTD.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/7\">",
"     7",
"    </a>",
"    ]. Meningococcal vaccination should also be used to control outbreaks of serogroup C meningococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/0/13322/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H21#H21\">",
"     \"Meningococcal vaccines\", section on 'In adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Those who have extensive contact with oropharyngeal secretions of infected patients should receive antimicrobial prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prevention of meningococcal infection\", section on 'Antimicrobial chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vaccines for other preventable diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare providers are not at increased risk of developing pneumococcal infections. They should receive these immunizations according to the",
"    <a class=\"external\" href=\"file://www.cdc.gov/vaccines/schedules/downloads/adult/adult-schedule.pdf\">",
"     schedule recommended",
"    </a>",
"    for healthy adults (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"UTD.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"     \"Approach to immunizations in healthy adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     APPROACH TO POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postexposure prophylaxis is indicated for susceptible healthcare providers who are exposed to hepatitis B, hepatitis C, HIV, influenza, measles, varicella, hepatitis A, pertussis, and meningococcus (",
"    <a class=\"graphic graphic_table graphicRef82359 graphicRef60692 \" href=\"UTD.htm?3/33/3614\">",
"     table 1A-B",
"    </a>",
"    ). These issues are discussed separately on the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=see_link\">",
"     \"Management of healthcare personnel exposed to HIV\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       \"Patient information: Vaccines for adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       \"Patient information: Vaccines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4539759\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All medical facilities or health departments that provide direct patient care are encouraged to formulate and implement a comprehensive immunization policy for all healthcare providers (",
"      <a class=\"graphic graphic_figure graphicRef82634 \" href=\"UTD.htm?36/52/37701\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4539738\">",
"       'Immunization policies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unless the healthcare provider has a contraindication to vaccine administration, immunization is recommended when prior vaccine administration cannot be documented. (See",
"      <a class=\"local\" href=\"#H4539745\">",
"       'Medical documentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Failure to immunize is often related to either refusal of the healthcare provider (because of concerns regarding side effects or failure to recognize risk) or because of inadequate enforcement of immunization policy. (See",
"      <a class=\"local\" href=\"#H4539752\">",
"       'Failure to immunize'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The introduction of hepatitis B immunization among healthcare providers in the 1980s was associated with a 90 percent decline in acquisition rates over the next decade. Protective titers (anti-HBs &gt;10",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      develop in 95 to 99 percent of healthy adults who receive three intramuscular doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      . All healthcare providers should have serologic testing approximately 2 months after immunization. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hepatitis B vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All healthcare providers should be immune to measles, mumps, and rubella, which have been associated with nosocomial outbreaks. Based upon these observations, healthcare providers are considered at high risk of exposure to measles, mumps, and rubella and need full immunity to these diseases. Serologic screening before immunization is generally not considered necessary for people who have documentation of appropriate vaccination, prior serologic testing, or laboratory confirmation of prior infection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Measles, mumps, and rubella vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Influenza vaccination of healthcare providers reduces absenteeism and transmission of infection to hospitalized patients and is recommended annually for all healthcare providers; those who work with immunocompromised patients should be offered the inactivated vaccine rather than the live attenuated formulation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Influenza vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healthcare providers can acquire varicella infection through person-to-person, droplet, or airborne transmission from a patient with either primary varicella or herpes zoster.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"       Varicella vaccine",
"      </a>",
"      is recommended for non-immune healthcare providers because of the risk of serious complications of natural disease in adults and the risk of further transmission in healthcare facilities. Those with a history of varicella infection can be considered immune, but all others should have serologic testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=see_link\">",
"       \"Measles-mumps-rubella vaccination in high risk adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pertussis is highly contagious; transmission occurs by direct contact with respiratory secretions or large aerosol droplets. Due to the recognition of waning immunity in adults, documented nosocomial outbreaks, and the availability of a safe and effective vaccine, healthcare personnel who have direct patient contact should receive a single dose of Tdap (tetanus-diphtheria-acellular pertussis) as soon as feasible, if they have not previously received this vaccine. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vaccines that may be indicated in specified settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine immunizations for hepatitis A, meningococcus, or tuberculosis are not recommended. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vaccines that may be indicated in specified settings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/1\">",
"      Larson EL. APIC guideline for handwashing and hand antisepsis in health care settings. Am J Infect Control 1995; 23:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/2\">",
"      Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/3\">",
"      National Committee for Clinical Laboratory Standards. Protection of laboratory workers from infectious diseases transmitted by blood, body fluids, and tissue: Tentative guideline. NCCLS Document M29-T2, 1991; 11(No. l4):l.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control. Biosafety in microbiological and biomedical laboratories. HHS Publication No. 93-8595. Government Printing Office, Washington, DC, 1995.",
"    </li>",
"    <li>",
"     Flemming DO, Richardson JH, Tulis JJ, Vesley D. Laboratory Safety, Second Edition, ASM Press, Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/6\">",
"      Corbett EL, Muzangwa J, Chaka K, et al. Nursing and community rates of Mycobacterium tuberculosis infection among students in Harare, Zimbabwe. Clin Infect Dis 2007; 44:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/7\">",
"      Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/8\">",
"      Centers for Disease Control (CDC). Pilot study of a household survey to determine HIV seroprevalence. MMWR Morb Mortal Wkly Rep 1991; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/9\">",
"      L'Ecuyer PB, Miller M, Winters K, Fraser VJ. Tuberculosis, hepatitis B, rubella, rubeola, and varicella infection and immunity among medical school employees. Infect Control Hosp Epidemiol 1998; 19:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/10\">",
"      Shapiro CN, Tokars JI, Chamberland ME. Use of the hepatitis-B vaccine and infection with hepatitis B and C among orthopaedic surgeons. The American Academy of Orthopaedic Surgeons Serosurvey Study Committee. J Bone Joint Surg Am 1996; 78:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/11\">",
"      Panlilio AL, Shapiro CN, Schable CA, et al. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group. J Am Coll Surg 1995; 180:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/12\">",
"      Agerton TB, Mahoney FJ, Polish LB, Shapiro CN. Impact of the bloodborne pathogens standard on vaccination of healthcare workers with hepatitis B vaccine. Infect Control Hosp Epidemiol 1995; 16:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/13\">",
"      McArthur MA, Simor AE, Campbell B, McGeer A. Influenza and pneumococcal vaccination and tuberculin skin testing programs in long-term care facilities: where do we stand? Infect Control Hosp Epidemiol 1995; 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/14\">",
"      Nichol KL, Hauge M. Influenza vaccination of healthcare workers. Infect Control Hosp Epidemiol 1997; 18:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/15\">",
"      Steingart KR, Thomas AR, Dykewicz CA, Redd SC. Transmission of measles virus in healthcare settings during a communitywide outbreak. Infect Control Hosp Epidemiol 1999; 20:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/16\">",
"      Christian MA. Influenza and hepatitis B vaccine acceptance: a survey of health care workers. Am J Infect Control 1991; 19:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/17\">",
"      Doebbeling BN, Edmond MB, Davis CS, et al. Influenza vaccination of health care workers: evaluation of factors that are important in acceptance. Prev Med 1997; 26:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/18\">",
"      Lane NE, Paul RI, Bratcher DF, Stover BH. A survey of policies at children's hospitals regarding immunity of healthcare workers: are physicians protected? Infect Control Hosp Epidemiol 1997; 18:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/19\">",
"      Adal KA, Flowers RH, Anglim AM, et al. Prevention of nosocomial influenza. Infect Control Hosp Epidemiol 1996; 17:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/20\">",
"      Bolyard EA, Tablan OC, Williams WW, et al. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1998; 19:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/21\">",
"      DeCastro MG, Denys GA, Fauerbach LL, et al. APIC position paper: immunization. Association for Professionals in Infection and Epidemiology, Inc. Am J Infect Control 1999; 27:52.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Physicians Task Force on Adult Immunization and Infectious Disease Society of America. In: Guide for Adult Immunization, Third Edition, American College of Physicians, Philadelphia  p.1994.",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Health care personnel. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th Edition, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.94.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/24\">",
"      Krause PJ, Gross PA, Barrett TL, et al. Quality standard for assurance of measles immunity among health care workers. The Infectious Diseases Society of America. Infect Control Hosp Epidemiol 1994; 15:193.",
"     </a>",
"    </li>",
"    <li>",
"     Poland GA, Haiduven DJ. Adult immunizations in the health-care worker. In: APIC Infection Control and Applied Epidemiology, Olmsted R (Ed), Mosby, St. Louis 1996. p.24.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/26\">",
"      Beekmann SE, Doebbeling BN. Frontiers of occupational health. New vaccines, new prophylactic regimens, and management of the HIV-infected worker. Infect Dis Clin North Am 1997; 11:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/27\">",
"      Weber DJ, Rutala WA, Weigle K. Selection and use of vaccines for healthcare workers. Infect Control Hosp Epidemiol 1997; 18:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/28\">",
"      Thomas DL, Factor SH, Kelen GD, et al. Viral hepatitis in health care personnel at The Johns Hopkins Hospital. The seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection. Arch Intern Med 1993; 153:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/29\">",
"      Dienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol 1982; 115:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/30\">",
"      Gibas A, Blewett DR, Schoenfeld DA, Dienstag JL. Prevalence and incidence of viral hepatitis in health workers in the prehepatitis B vaccination era. Am J Epidemiol 1992; 136:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/31\">",
"      Hadler SC, Doto IL, Maynard JE, et al. Occupational risk of hepatitis B infection in hospital workers. Infect Control 1985; 6:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/32\">",
"      Lowenfels AB, Wormser GP, Jain R. Frequency of puncture injuries in surgeons and estimated risk of HIV infection. Arch Surg 1989; 124:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/33\">",
"      Tokars JI, Chamberland ME, Schable CA, et al. A survey of occupational blood contact and HIV infection among orthopedic surgeons. The American Academy of Orthopaedic Surgeons Serosurvey Study Committee. JAMA 1992; 268:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/34\">",
"      Hibberd PL. Patients, needles, and healthcare workers: understanding the epidemiology, pathophysiology, and transmission of the human immunodeficiency virus, hepatitis B and C, and cytomegalovirus. J Intraven Nurs 1995; 18:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/35\">",
"      Kew MC. Possible transmission of serum (Australia-antigen-positive) hepatitis via the conjunctiva. Infect Immun 1973; 7:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/36\">",
"      Snydman DR, Hindman SH, Wineland MD, et al. Nosocomial viral hepatitis B. A cluster among staff with subsequent transmission to patients. Ann Intern Med 1976; 85:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/37\">",
"      Ingerslev J, Mortensen E, Rasmussen K, et al. Silent hepatitis-B immunization in laboratory technicians. Scand J Clin Lab Invest 1988; 48:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/38\">",
"      Handsfield HH, Cummings MJ, Swenson PD. Prevalence of antibody to human immunodeficiency virus and hepatitis B surface antigen in blood samples submitted to a hospital laboratory. Implications for handling specimens. JAMA 1987; 258:3395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/39\">",
"      Centers for Disease Control (CDC). Hepatitis B associated with jet gun injection--California. MMWR Morb Mortal Wkly Rep 1986; 35:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/40\">",
"      Morris IM, Cattle DS, Smits BJ. Letter: Endoscopy and transmission of hepatitis B. Lancet 1975; 2:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/41\">",
"      Oren I, Hershow RC, Ben-Porath E, et al. A common-source outbreak of fulminant hepatitis B in a hospital. Ann Intern Med 1989; 110:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/42\">",
"      Centers for Disease Control (CDC). Nosocomial transmission of hepatitis B virus associated with a spring-loaded fingerstick device--California. MMWR Morb Mortal Wkly Rep 1990; 39:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/43\">",
"      Polish LB, Shapiro CN, Bauer F, et al. Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded finger-stick device. N Engl J Med 1992; 326:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/44\">",
"      Centers for Disease Control and Prevention (CDC). Nosocomial hepatitis B virus infection associated with reusable fingerstick blood sampling devices--Ohio and New York City, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/45\">",
"      Lauer JL, VanDrunen NA, Washburn JW, Balfour HH Jr. Transmission of hepatitis B virus in clinical laboratory areas. J Infect Dis 1979; 140:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/46\">",
"      Pattison CP, Boyer DM, Maynard JE, Kelly PC. Epidemic hepatitis in a clinical laboratory. Possible association with computer card handling. JAMA 1974; 230:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/47\">",
"      Tanaka S, Yoshiba M, Iino S, et al. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. Kidney Int 1995; 48:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/48\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of hepatitis B virus infection among hemodialysis patients-- California, Nebraska, and Texas, 1994. MMWR Morb Mortal Wkly Rep 1996; 45:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/49\">",
"      Weber DJ, Hoffmann KK, Rutala WA. Management of the healthcare worker infected with human immunodeficiency virus: lessons from nosocomial transmission of hepatitis B virus. Infect Control Hosp Epidemiol 1991; 12:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/50\">",
"      Bell DM, Shapiro CN, Ciesielski CA, Chamberland ME. Preventing bloodborne pathogen transmission from health-care workers to patients. The CDC perspective. Surg Clin North Am 1995; 75:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/51\">",
"      Harpaz R, Von Seidlein L, Averhoff FM, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996; 334:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/52\">",
"      Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. The Incident Investigation Teams and others. N Engl J Med 1997; 336:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/53\">",
"      Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:4077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/54\">",
"      Department of Labor. Bloodborne pathogens: the standard. Federal Register 1991; 60:64175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/55\">",
"      Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/56\">",
"      Poland GA. Hepatitis B immunization in health care workers. Dealing with vaccine nonresponse. Am J Prev Med 1998; 15:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/57\">",
"      Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989; 160:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/58\">",
"      Hadler SC, de Monzon MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 1989; 7:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/59\">",
"      Havlichek D Jr, Rosenman K, Simms M, Guss P. Age-related hepatitis B seroconversion rates in health care workers. Am J Infect Control 1997; 25:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/60\">",
"      Louther J, Feldman J, Rivera P, et al. Hepatitis B vaccination program at a New York City hospital: seroprevalence, seroconversion, and declination. Am J Infect Control 1998; 26:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/61\">",
"      Alimonos K, Nafziger AN, Murray J, Bertino JS Jr. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin Infect Dis 1998; 26:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/62\">",
"      Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/63\">",
"      Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/64\">",
"      Centers for Disease Control and Prevention (CDC). Injuries and deaths associated with use of snowmobiles--Maine, 1991-1996. MMWR Morb Mortal Wkly Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Current topics in infectious diseases, Remington JS, Swartz MN (Eds), Blackwell Science, Boston 1992. p.282.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/66\">",
"      Balkovic ES, Goodman RA, Rose FB, Borel CO. Nosocomial influenza A (H1N1) infection. Am J Med Technol 1980; 46:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/67\">",
"      Van Voris LP, Belshe RB, Shaffer JL. Nosocomial influenza B virus infection in the elderly. Ann Intern Med 1982; 96:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/68\">",
"      Centers for Disease Control (CDC). Suspected nosocomial influenza cases in an intensive care unit. MMWR Morb Mortal Wkly Rep 1988; 37:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/69\">",
"      Pachucki CT, Pappas SA, Fuller GF, et al. Influenza A among hospital personnel and patients. Implications for recognition, prevention, and control. Arch Intern Med 1989; 149:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/70\">",
"      Hammond GW, Cheang M. Absenteeism among hospital staff during an influenza epidemic: implications for immunoprophylaxis. Can Med Assoc J 1984; 131:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/71\">",
"      Patriarca PA, Weber JA, Parker RA, et al. Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J Epidemiol 1986; 124:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/72\">",
"      Gross PA, Rodstein M, LaMontagne JR, et al. Epidemiology of acute respiratory illness during an influenza outbreak in a nursing home. A prospective study. Arch Intern Med 1988; 148:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/73\">",
"      Cartter ML, Renzullo PO, Helgerson SD, et al. Influenza outbreaks in nursing homes: how effective is influenza vaccine in the institutionalized elderly? Infect Control Hosp Epidemiol 1990; 11:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/74\">",
"      Arroyo JC, Postic B, Brown A, et al. Influenza A/Philippines/2/82 outbreak in a nursing home: limitations of influenza vaccination in the aged. Am J Infect Control 1984; 12:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/75\">",
"      Christie RW, Marquis LL. Immunization roulette: influenza occurrence in five nursing homes. Am J Infect Control 1985; 13:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/76\">",
"      Atkinson WL, Arden NH, Patriarca PA, et al. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch Intern Med 1986; 146:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/77\">",
"      Centers for Disease Control (CDC). Outbreak of influenza A in a nursing home--New York, December 1991-January 1992. MMWR Morb Mortal Wkly Rep 1992; 41:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/78\">",
"      Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/79\">",
"      Tablan OC, Anderson LJ, Arden NH, et al. Guideline for prevention of nosocomial pneumonia. The Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Infect Control Hosp Epidemiol 1994; 15:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/80\">",
"      Gomolin IH, Leib HB, Arden NH, Sherman FT. Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management. J Am Geriatr Soc 1995; 43:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/81\">",
"      Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/82\">",
"      Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/83\">",
"      Sax&eacute;n H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatr Infect Dis J 1999; 18:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/84\">",
"      Talbot TR, Babcock H, Cotton D, et al. The use of live attenuated influenza vaccine (LAIV) in healthcare personnel (HCP): guidance from the Society for Healthcare Epidemiology of America (SHEA). Infect Control Hosp Epidemiol 2012; 33:981.",
"     </a>",
"    </li>",
"    <li>",
"     wonder.cdc.gov/mmwr/mmwr_reps.asp?mmwr_table=3A&amp;mmwr_year=1999&amp;mmwr_week=52 (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     wonder.cdc.gov/mmwr/mmwr_reps.asp?mmwr_table=3B&amp;mmwr_year=1999&amp;mmwr_week=52 (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/87\">",
"      Williams WW, Preblud SR, Reichelderfer PS, Hadler SC. Vaccines of importance in the hospital setting. Problems and developments. Infect Dis Clin North Am 1989; 3:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/88\">",
"      Fischer PR, Brunetti C, Welch V, Christenson JC. Nosocomial mumps: report of an outbreak and its control. Am J Infect Control 1996; 24:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/89\">",
"      McGrath D, Swanson R, Weems S, et al. Analysis of a measles outbreak in Kent County, Michigan in 1990. Pediatr Infect Dis J 1992; 11:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/90\">",
"      Rivera ME, Mason WH, Ross LA, Wright HT Jr. Nosocomial measles infection in a pediatric hospital during a community-wide epidemic. J Pediatr 1991; 119:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/91\">",
"      Miranda AC, Falc&atilde;o J, Dias JA, et al. Measles transmission in health facilities during outbreaks. Int J Epidemiol 1994; 23:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/92\">",
"      Remington PL, Hall WN, Davis IH, et al. Airborne transmission of measles in a physician's office. JAMA 1985; 253:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/93\">",
"      Bloch AB, Orenstein WA, Ewing WM, et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics 1985; 75:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/94\">",
"      Centers for Disease Control (CDC). Nosocomial rubella infection - North Dakota, Alabama, Ohio. MMWR Morb Mortal Wkly Rep 1981; 29:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/95\">",
"      Watkins NM, Smith RP Jr, St Germain DL, MacKay DN. Measles (rubeola) infection in a hospital setting. Am J Infect Control 1987; 15:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/96\">",
"      Braunstein H, Thomas S, Ito R. Immunity to measles in a large population of varying age. Significance with respect to vaccination. Am J Dis Child 1990; 144:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/97\">",
"      Smith E, Wong VK. Measles susceptibility of hospital personnel. Arch Intern Med 1993; 153:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/98\">",
"      Mortimer EA Jr. Pertussis and its prevention: a family affair. J Infect Dis 1990; 161:473.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/pertussis/outbreaks.html (Accessed on July 06, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pert.pdf (Accessed on July 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/101\">",
"      Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years --- United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/102\">",
"      Centers for Disease Control and Prevention (CDC). Tetanus and pertussis vaccination coverage among adults aged &ge; 18 years --- United States, 1999 and 2008. MMWR Morb Mortal Wkly Rep 2010; 59:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/103\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/104\">",
"      Josephson A, Karanfil L, Gombert ME. Strategies for the management of varicella-susceptible healthcare workers after a known exposure. Infect Control Hosp Epidemiol 1990; 11:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/105\">",
"      Weber DJ, Rutala WA, Parham C. Impact and costs of varicella prevention in a university hospital. Am J Public Health 1988; 78:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/106\">",
"      Josephson A, Gombert ME. Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 1988; 158:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/107\">",
"      Varicella and zoster in hospitals. Lancet 1990; 335:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/108\">",
"      Friedman CA, Temple DM, Robbins KK, et al. Outbreak and control of varicella in a neonatal intensive care unit. Pediatr Infect Dis J 1994; 13:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/109\">",
"      Faoagali JL, Darcy D. Chickenpox outbreak among the staff of a large, urban adult hospital: costs of monitoring and control. Am J Infect Control 1995; 23:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/110\">",
"      Krasinski K, Holzman RS, LaCouture R, Florman A. Hospital experience with varicella-zoster virus. Infect Control 1986; 7:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/111\">",
"      Nettleman MD, Schmid M. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers. Infect Control Hosp Epidemiol 1997; 18:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/112\">",
"      Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/113\">",
"      Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     wonder.cdc.gov/mmwr/mmwr_reps.asp?mmwr_table=3A&amp;mmwr_year=2001&amp;mmwr_week=52 (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control. Hepatitis Surveillance Report No. 56. Public Health Service, Centers for Disease Control. Atlanta, US Department of Health and Human Services, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/116\">",
"      Papaevangelou GJ, Roumeliotou-Karayannis AJ, Contoyannis PC. The risk of nosocomial hepatitis A and B virus infections from patients under care without isolation precaution. J Med Virol 1981; 7:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/117\">",
"      Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 1991; 164:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/118\">",
"      Lee KK, Vargo LR, L&ecirc; CT, Fernando L. Transfusion-acquired hepatitis A outbreak from fresh frozen plasma in a neonatal intensive care unit. Pediatr Infect Dis J 1992; 11:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/119\">",
"      EISENSTEIN AB, AACH RD, JACOBSOHN W, GOLDMAN A. AN EPIDEMIC OF INFECTIOUS HEPATITIS IN A GENERAL HOSPITAL. PROBABLE TRANSMISSION BY CONTAMINATED ORANGE JUICE. JAMA 1963; 185:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/120\">",
"      Meyers JD, Romm FJ, Tihen WS, Bryan JA. Food-borne hepatitis A in a general hospital. Epidemiologic study of an outbreak attributed to sandwiches. JAMA 1975; 231:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/121\">",
"      Watson JC, Fleming DW, Borella AJ, et al. Vertical transmission of hepatitis A resulting in an outbreak in a neonatal intensive care unit. J Infect Dis 1993; 167:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/122\">",
"      Doebbeling BN, Li N, Wenzel RP. An outbreak of hepatitis A among health care workers: risk factors for transmission. Am J Public Health 1993; 83:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/123\">",
"      Burkholder BT, Coronado VG, Brown J, et al. Nosocomial transmission of hepatitis A in a pediatric hospital traced to an anti-hepatitis A virus-negative patient with immunodeficiency. Pediatr Infect Dis J 1995; 14:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/0/13322/abstract/124\">",
"      Hanna JN, Loewenthal MR, Negel P, Wenck DJ. An outbreak of hepatitis A in an intensive care unit. Anaesth Intensive Care 1996; 24:440.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3889 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-854D70C629-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13322=[""].join("\n");
var outline_f13_0_13322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4539759\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHICH HEALTHCARE PROVIDERS SHOULD BE IMMUNIZED AGAINST VACCINE-PREVENTABLE DISEASES?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4539738\">",
"      Immunization policies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4539745\">",
"      Medical documentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4539752\">",
"      Failure to immunize",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WHICH VACCINES SHOULD BE PROVIDED TO HEALTHCARE PROVIDERS?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hepatitis B vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nonresponders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fall in antibody titers over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Measles, mumps, and rubella vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19145659\">",
"      Pertussis vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Varicella vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vaccines that may be indicated in specified settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - BCG vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hepatitis A vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Meningococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vaccines for other preventable diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      APPROACH TO POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4539759\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3889\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3889|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/52/37701\" title=\"figure 1\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42263\" title=\"figure 2\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3889|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/35/4669\" title=\"table 1A\">",
"      HCW prophylaxis recs I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/31/31228\" title=\"table 1B\">",
"      HCW prophylaxis recs II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=related_link\">",
"      BCG vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14822?source=related_link\">",
"      Measles-mumps-rubella vaccination in high risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/28/32200?source=related_link\">",
"      Prevention and control of varicella in hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25609?source=related_link\">",
"      Treatment and prevention of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_0_13323="Child Turcotte classification";
var content_f13_0_13323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Child Turcotte classification of patients with cirrhosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Parameter",
"      </td>",
"      <td class=\"subtitle1\">",
"       A",
"      </td>",
"      <td class=\"subtitle1\">",
"       B",
"      </td>",
"      <td class=\"subtitle1\">",
"       C",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ascites",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Easily controlled",
"      </td>",
"      <td>",
"       Poorly controlled",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bilirubin",
"      </td>",
"      <td>",
"       &lt;2 mg/dL (&lt;34.2 micromol/liter)",
"      </td>",
"      <td>",
"       2-3 mg/dL (34.2 to 51.3 micromol/liter)",
"      </td>",
"      <td>",
"       &gt;3 mg/dL (&gt;51.3 micromol/liter)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Albumin",
"      </td>",
"      <td>",
"       &gt;3.5 g/dL (&gt;35 g/liter)",
"      </td>",
"      <td>",
"       3.0-3.5 g/dL (30 to 35 g/liter)",
"      </td>",
"      <td>",
"       &lt;3.0 g/dL (&lt;30 g/liter)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Encephalopathy",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Mild",
"      </td>",
"      <td>",
"       Advanced",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nutritional status",
"      </td>",
"      <td>",
"       Excellent",
"      </td>",
"      <td>",
"       Good",
"      </td>",
"      <td>",
"       Poor",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13323=[""].join("\n");
var outline_f13_0_13323=null;
var title_f13_0_13324="DTP adverse reaction rates";
var content_f13_0_13324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated rates of moderate and severe adverse reactions after diphtheria-tetanus-whole cell pertussis (DTwP) and diphtheria-tetanus-acellular pertussis (DTaP) vaccines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Adverse reaction",
"       </td>",
"       <td class=\"subtitle1\">",
"        DTwP",
"       </td>",
"       <td class=\"subtitle1\">",
"        DTaP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Entire limb swelling",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 in 33 to 1 in 50 children after the fourth or fifth dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent inconsolable crying (&ge;3 hours)",
"       </td>",
"       <td>",
"        1 in 100 doses",
"       </td>",
"       <td>",
"        1 in 1000 children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotonic-hyporesponsive episode (collapse, shock-like state)",
"       </td>",
"       <td>",
"        1 in 1750 doses (range 1 in 344 to 1 in 28,570)",
"       </td>",
"       <td>",
"        Less than 1 per 10,000 children (range 1 in 714 to 1 in 25,000)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures (febrile)",
"       </td>",
"       <td>",
"        1 in 1750 doses",
"       </td>",
"       <td>",
"        1 in 14,000 children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever &ge;105&deg;F (40.5&deg;C)",
"       </td>",
"       <td>",
"        1 in 333 doses",
"       </td>",
"       <td>",
"        1 in 16,000 children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylaxis",
"       </td>",
"       <td>",
"        1 in 50,000 doses",
"       </td>",
"       <td>",
"        Less than 1 in 1 million doses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     1. American Academy of Pediatrics. Pertussis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.553.",
"     <br>",
"      2. US Department of Health and Human Services. Centers for Disease Control and Prevention. Vaccine Information Statement DTaP (5/17/07). Available at: www.cdc.gov/vaccines/pubs/vis/default.htm#dtap. Accessed on June 25, 2012.",
"      <br>",
"       3.&nbsp;Centers for Disease Control and Prevention. Pertussis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink book, 12th ed. Atkinson W, Wolfe S, Hamborsky J (Eds). Public Health Foundation, Washington, DC 2012. Available at: www.cdc.gov/vaccines/pubs/pinkbook/index.html.&nbsp;Accessed on June 25, 2012.",
"       <br>",
"        4. &nbsp;Gold MS. Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern?. Drug Saf 2002; 25:85.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13324=[""].join("\n");
var outline_f13_0_13324=null;
var title_f13_0_13325="Frequency of dialysis and BUN";
var content_f13_0_13325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing the number of required dialysis treatments to obtain target BUN concentration in hypermetabolic patients with acute kidney injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 221px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The number of hemodialysis treatments per week required to obtain a particular average concentration of BUN in hypercatabolic patients with acute renal failure varies with patient weight (x axis). A, B, and C are the three curves associated with target BUN levels of 100, 80, and 60 mg/dL, respectively.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Clark, WR, Mueller, BA, Kraus, MA, Macias, WL, J Am Soc Nephrol 1997; 8:804",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13325=[""].join("\n");
var outline_f13_0_13325=null;
var title_f13_0_13326="Contents: Travel health";
var content_f13_0_13326=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Travel health",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Travel health",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Food poisoning",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/42/2723\">",
"           Patient information: Campylobacter infection (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/63/31730\">",
"           Patient information: E. coli (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10595\">",
"           Patient information: Food poisoning (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/30/29156\">",
"           Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28114\">",
"           Patient information: Listeria (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/57/28562\">",
"           Patient information: Nausea and vomiting in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27858\">",
"           Patient information: Rotavirus infection (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/31/27122\">",
"           Patient information: Salmonellosis (Salmonella) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38305\">",
"           Patient information: Typhoid fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9267\">",
"           Patient information: Viral gastroenteritis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         High-altitude travel",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/18/23842\">",
"           Patient information: Altitude sickness (including mountain sickness) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4403\">",
"           Patient information: High altitude illness (including mountain sickness) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Insect borne disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/27/16818\">",
"           Patient information: Dengue fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/40/30338\">",
"           Patient information: Lyme disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/0/27649\">",
"           Patient information: Lyme disease prevention (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/17/32022\">",
"           Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/41/5778\">",
"           Patient information: Lyme disease treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/47/3826\">",
"           Patient information: Malaria (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/2/22562\">",
"           Patient information: Rocky Mountain spotted fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/19/16690\">",
"           Patient information: West Nile virus infection (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/10/13474\">",
"           Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Jet lag",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/9/19602\">",
"           Patient information: Jet lag (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Travel advice",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/2/16421\">",
"           Patient information: General travel advice (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/42/27298\">",
"           Patient information: Staying healthy when you travel (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33122\">",
"           Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38305\">",
"           Patient information: Typhoid fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/44/21187\">",
"           Patient information: Vaccines for travel (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-0A34E8F9EC-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f13_0_13326=[""].join("\n");
var outline_f13_0_13326=null;
var title_f13_0_13327="IV GTT";
var content_f13_0_13327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    IV GTT k values derived from quotients: Q = 10 minute glucose/60 minute glucose",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Q",
"       </td>",
"       <td class=\"subtitle1\">",
"        k",
"       </td>",
"       <td rowspan=\"41\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Q",
"       </td>",
"       <td class=\"subtitle1\">",
"        k",
"       </td>",
"       <td rowspan=\"41\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Q",
"       </td>",
"       <td class=\"subtitle1\">",
"        k",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.284",
"       </td>",
"       <td class=\"centered\">",
"        0.50",
"       </td>",
"       <td class=\"centered\">",
"        1.568",
"       </td>",
"       <td class=\"centered\">",
"        0.90",
"       </td>",
"       <td class=\"centered\">",
"        1.916",
"       </td>",
"       <td class=\"centered\">",
"        1.30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.290",
"       </td>",
"       <td class=\"centered\">",
"        0.51",
"       </td>",
"       <td class=\"centered\">",
"        1.576",
"       </td>",
"       <td class=\"centered\">",
"        0.91",
"       </td>",
"       <td class=\"centered\">",
"        1.925",
"       </td>",
"       <td class=\"centered\">",
"        1.31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.297",
"       </td>",
"       <td class=\"centered\">",
"        0.52",
"       </td>",
"       <td class=\"centered\">",
"        1.584",
"       </td>",
"       <td class=\"centered\">",
"        0.92",
"       </td>",
"       <td class=\"centered\">",
"        1.935",
"       </td>",
"       <td class=\"centered\">",
"        1.32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.303",
"       </td>",
"       <td class=\"centered\">",
"        0.53",
"       </td>",
"       <td class=\"centered\">",
"        1.592",
"       </td>",
"       <td class=\"centered\">",
"        0.93",
"       </td>",
"       <td class=\"centered\">",
"        1.944",
"       </td>",
"       <td class=\"centered\">",
"        1.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.310",
"       </td>",
"       <td class=\"centered\">",
"        0.54",
"       </td>",
"       <td class=\"centered\">",
"        1.600",
"       </td>",
"       <td class=\"centered\">",
"        0.94",
"       </td>",
"       <td class=\"centered\">",
"        1.954",
"       </td>",
"       <td class=\"centered\">",
"        1.34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.316",
"       </td>",
"       <td class=\"centered\">",
"        0.55",
"       </td>",
"       <td class=\"centered\">",
"        1.608",
"       </td>",
"       <td class=\"centered\">",
"        0.95",
"       </td>",
"       <td class=\"centered\">",
"        1.964",
"       </td>",
"       <td class=\"centered\">",
"        1.35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.323",
"       </td>",
"       <td class=\"centered\">",
"        0.56",
"       </td>",
"       <td class=\"centered\">",
"        1.616",
"       </td>",
"       <td class=\"centered\">",
"        0.96",
"       </td>",
"       <td class=\"centered\">",
"        1.974",
"       </td>",
"       <td class=\"centered\">",
"        1.36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.330",
"       </td>",
"       <td class=\"centered\">",
"        0.57",
"       </td>",
"       <td class=\"centered\">",
"        1.624",
"       </td>",
"       <td class=\"centered\">",
"        0.97",
"       </td>",
"       <td class=\"centered\">",
"        1.984",
"       </td>",
"       <td class=\"centered\">",
"        1.37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.336",
"       </td>",
"       <td class=\"centered\">",
"        0.58",
"       </td>",
"       <td class=\"centered\">",
"        1.632",
"       </td>",
"       <td class=\"centered\">",
"        0.98",
"       </td>",
"       <td class=\"centered\">",
"        1.994",
"       </td>",
"       <td class=\"centered\">",
"        1.38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.343",
"       </td>",
"       <td class=\"centered\">",
"        0.59",
"       </td>",
"       <td class=\"centered\">",
"        1.640",
"       </td>",
"       <td class=\"centered\">",
"        0.99",
"       </td>",
"       <td class=\"centered\">",
"        2.004",
"       </td>",
"       <td class=\"centered\">",
"        1.39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.350",
"       </td>",
"       <td class=\"centered\">",
"        0.60",
"       </td>",
"       <td class=\"centered\">",
"        1.649",
"       </td>",
"       <td class=\"centered\">",
"        1.00",
"       </td>",
"       <td class=\"centered\">",
"        2.014",
"       </td>",
"       <td class=\"centered\">",
"        1.40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.357",
"       </td>",
"       <td class=\"centered\">",
"        0.61",
"       </td>",
"       <td class=\"centered\">",
"        1.657",
"       </td>",
"       <td class=\"centered\">",
"        1.01",
"       </td>",
"       <td class=\"centered\">",
"        2.024",
"       </td>",
"       <td class=\"centered\">",
"        1.41",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.364",
"       </td>",
"       <td class=\"centered\">",
"        0.62",
"       </td>",
"       <td class=\"centered\">",
"        1.665",
"       </td>",
"       <td class=\"centered\">",
"        1.02",
"       </td>",
"       <td class=\"centered\">",
"        2.034",
"       </td>",
"       <td class=\"centered\">",
"        1.42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.370",
"       </td>",
"       <td class=\"centered\">",
"        0.63",
"       </td>",
"       <td class=\"centered\">",
"        1.674",
"       </td>",
"       <td class=\"centered\">",
"        1.03",
"       </td>",
"       <td class=\"centered\">",
"        2.044",
"       </td>",
"       <td class=\"centered\">",
"        1.43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.377",
"       </td>",
"       <td class=\"centered\">",
"        0.64",
"       </td>",
"       <td class=\"centered\">",
"        1.682",
"       </td>",
"       <td class=\"centered\">",
"        1.04",
"       </td>",
"       <td class=\"centered\">",
"        2.054",
"       </td>",
"       <td class=\"centered\">",
"        1.44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.384",
"       </td>",
"       <td class=\"centered\">",
"        0.65",
"       </td>",
"       <td class=\"centered\">",
"        1.690",
"       </td>",
"       <td class=\"centered\">",
"        1.05",
"       </td>",
"       <td class=\"centered\">",
"        2.065",
"       </td>",
"       <td class=\"centered\">",
"        1.45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.391",
"       </td>",
"       <td class=\"centered\">",
"        0.66",
"       </td>",
"       <td class=\"centered\">",
"        1.699",
"       </td>",
"       <td class=\"centered\">",
"        1.06",
"       </td>",
"       <td class=\"centered\">",
"        2.075",
"       </td>",
"       <td class=\"centered\">",
"        1.46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.398",
"       </td>",
"       <td class=\"centered\">",
"        0.67",
"       </td>",
"       <td class=\"centered\">",
"        1.707",
"       </td>",
"       <td class=\"centered\">",
"        1.07",
"       </td>",
"       <td class=\"centered\">",
"        2.086",
"       </td>",
"       <td class=\"centered\">",
"        1.47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.405",
"       </td>",
"       <td class=\"centered\">",
"        0.68",
"       </td>",
"       <td class=\"centered\">",
"        1.716",
"       </td>",
"       <td class=\"centered\">",
"        1.08",
"       </td>",
"       <td class=\"centered\">",
"        2.096",
"       </td>",
"       <td class=\"centered\">",
"        1.48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.412",
"       </td>",
"       <td class=\"centered\">",
"        0.69",
"       </td>",
"       <td class=\"centered\">",
"        1.725",
"       </td>",
"       <td class=\"centered\">",
"        1.09",
"       </td>",
"       <td class=\"centered\">",
"        2.110",
"       </td>",
"       <td class=\"centered\">",
"        1.49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.419",
"       </td>",
"       <td class=\"centered\">",
"        0.70",
"       </td>",
"       <td class=\"centered\">",
"        1.733",
"       </td>",
"       <td class=\"centered\">",
"        1.10",
"       </td>",
"       <td class=\"centered\">",
"        2.117",
"       </td>",
"       <td class=\"centered\">",
"        1.50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.426",
"       </td>",
"       <td class=\"centered\">",
"        0.71",
"       </td>",
"       <td class=\"centered\">",
"        1.742",
"       </td>",
"       <td class=\"centered\">",
"        1.11",
"       </td>",
"       <td class=\"centered\">",
"        2.128",
"       </td>",
"       <td class=\"centered\">",
"        1.51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.433",
"       </td>",
"       <td class=\"centered\">",
"        0.72",
"       </td>",
"       <td class=\"centered\">",
"        1.751",
"       </td>",
"       <td class=\"centered\">",
"        1.12",
"       </td>",
"       <td class=\"centered\">",
"        2.138",
"       </td>",
"       <td class=\"centered\">",
"        1.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.441",
"       </td>",
"       <td class=\"centered\">",
"        0.73",
"       </td>",
"       <td class=\"centered\">",
"        1.759",
"       </td>",
"       <td class=\"centered\">",
"        1.13",
"       </td>",
"       <td class=\"centered\">",
"        2.149",
"       </td>",
"       <td class=\"centered\">",
"        1.53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.448",
"       </td>",
"       <td class=\"centered\">",
"        0.74",
"       </td>",
"       <td class=\"centered\">",
"        1.768",
"       </td>",
"       <td class=\"centered\">",
"        1.14",
"       </td>",
"       <td class=\"centered\">",
"        2.160",
"       </td>",
"       <td class=\"centered\">",
"        1.54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.455",
"       </td>",
"       <td class=\"centered\">",
"        0.75",
"       </td>",
"       <td class=\"centered\">",
"        1.777",
"       </td>",
"       <td class=\"centered\">",
"        1.15",
"       </td>",
"       <td class=\"centered\">",
"        2.171",
"       </td>",
"       <td class=\"centered\">",
"        1.55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.462",
"       </td>",
"       <td class=\"centered\">",
"        0.76",
"       </td>",
"       <td class=\"centered\">",
"        1.786",
"       </td>",
"       <td class=\"centered\">",
"        1.16",
"       </td>",
"       <td class=\"centered\">",
"        2.182",
"       </td>",
"       <td class=\"centered\">",
"        1.56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.470",
"       </td>",
"       <td class=\"centered\">",
"        0.77",
"       </td>",
"       <td class=\"centered\">",
"        1.795",
"       </td>",
"       <td class=\"centered\">",
"        1.17",
"       </td>",
"       <td class=\"centered\">",
"        2.193",
"       </td>",
"       <td class=\"centered\">",
"        1.57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.477",
"       </td>",
"       <td class=\"centered\">",
"        0.78",
"       </td>",
"       <td class=\"centered\">",
"        1.804",
"       </td>",
"       <td class=\"centered\">",
"        1.18",
"       </td>",
"       <td class=\"centered\">",
"        2.204",
"       </td>",
"       <td class=\"centered\">",
"        1.58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.484",
"       </td>",
"       <td class=\"centered\">",
"        0.79",
"       </td>",
"       <td class=\"centered\">",
"        1.813",
"       </td>",
"       <td class=\"centered\">",
"        1.19",
"       </td>",
"       <td class=\"centered\">",
"        2.214",
"       </td>",
"       <td class=\"centered\">",
"        1.59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.492",
"       </td>",
"       <td class=\"centered\">",
"        0.80",
"       </td>",
"       <td class=\"centered\">",
"        1.822",
"       </td>",
"       <td class=\"centered\">",
"        1.20",
"       </td>",
"       <td class=\"centered\">",
"        2.226",
"       </td>",
"       <td class=\"centered\">",
"        1.60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.499",
"       </td>",
"       <td class=\"centered\">",
"        0.81",
"       </td>",
"       <td class=\"centered\">",
"        1.831",
"       </td>",
"       <td class=\"centered\">",
"        1.21",
"       </td>",
"       <td class=\"centered\">",
"        2.237",
"       </td>",
"       <td class=\"centered\">",
"        1.61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.507",
"       </td>",
"       <td class=\"centered\">",
"        0.82",
"       </td>",
"       <td class=\"centered\">",
"        1.844",
"       </td>",
"       <td class=\"centered\">",
"        1.22",
"       </td>",
"       <td class=\"centered\">",
"        2.247",
"       </td>",
"       <td class=\"centered\">",
"        1.62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.514",
"       </td>",
"       <td class=\"centered\">",
"        0.83",
"       </td>",
"       <td class=\"centered\">",
"        1.850",
"       </td>",
"       <td class=\"centered\">",
"        1.23",
"       </td>",
"       <td class=\"centered\">",
"        2.259",
"       </td>",
"       <td class=\"centered\">",
"        1.63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.522",
"       </td>",
"       <td class=\"centered\">",
"        0.84",
"       </td>",
"       <td class=\"centered\">",
"        1.859",
"       </td>",
"       <td class=\"centered\">",
"        1.24",
"       </td>",
"       <td class=\"centered\">",
"        2.271",
"       </td>",
"       <td class=\"centered\">",
"        1.64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.530",
"       </td>",
"       <td class=\"centered\">",
"        0.85",
"       </td>",
"       <td class=\"centered\">",
"        1.863",
"       </td>",
"       <td class=\"centered\">",
"        1.25",
"       </td>",
"       <td class=\"centered\">",
"        2.282",
"       </td>",
"       <td class=\"centered\">",
"        1.65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.537",
"       </td>",
"       <td class=\"centered\">",
"        0.86",
"       </td>",
"       <td class=\"centered\">",
"        1.878",
"       </td>",
"       <td class=\"centered\">",
"        1.26",
"       </td>",
"       <td class=\"centered\">",
"        2.294",
"       </td>",
"       <td class=\"centered\">",
"        1.66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.545",
"       </td>",
"       <td class=\"centered\">",
"        0.87",
"       </td>",
"       <td class=\"centered\">",
"        1.887",
"       </td>",
"       <td class=\"centered\">",
"        1.27",
"       </td>",
"       <td class=\"centered\">",
"        2.307",
"       </td>",
"       <td class=\"centered\">",
"        1.67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.553",
"       </td>",
"       <td class=\"centered\">",
"        0.88",
"       </td>",
"       <td class=\"centered\">",
"        1.896",
"       </td>",
"       <td class=\"centered\">",
"        1.28",
"       </td>",
"       <td class=\"centered\">",
"        2.316",
"       </td>",
"       <td class=\"centered\">",
"        1.68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1.561",
"       </td>",
"       <td class=\"centered\">",
"        0.89",
"       </td>",
"       <td class=\"centered\">",
"        1.906",
"       </td>",
"       <td class=\"centered\">",
"        1.29",
"       </td>",
"       <td class=\"centered\">",
"        2.329",
"       </td>",
"       <td class=\"centered\">",
"        1.69",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Posner NA, Silverstone FA, Brewer J, Heller M. Simplifying the intravenous glucose tolerance test. J Reprod Med 1982; 27:633. Copyright &copy; 1982 Journal of Reproductive Medicine, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_0_13327=[""].join("\n");
var outline_f13_0_13327=null;
